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T
he present report presents findings
from a research project undertaken
by Merchants Quay Ireland (MQI).
The evidence emerging from international
studies points to a significant increase in the
prevalence of individuals attending harm
reduction services who are users of
performance and image enhancing drugs
(PIEDs). Given the indicators of a similar
trend emerging in an Irish context, the
rationale underlying the study was based on
the recognition of the growing need to
examine the profile and perspectives of such
individuals attending services in Ireland.
The study employed a mixed method
research design, with 89 clients of harm
reduction services, who were users of
PIEDs, completing a comprehensive survey.
An overview of the nine primary questions,
which the research aimed to address, is
provided below, with a description of the
main findings relevant to each question also
presented.
What is the socio-demographic profile?
The average PIED user in the present study
was approximately 27 years of age, although
the age of participants ranged from 18 to 40
years old. All participants were male and
significantly, no female PIED users
presented during the period of data
collection. While the sample was comprised
of eight different nationalities, the vast
majority were Irish nationals (90%). The
dominant ethnic/cultural background was
White Irish (80.9%), with few participants
reporting Black or Asian backgrounds. Most
of the participants reported a heterosexual
sexual orientation (90.9%). The most
common categories of current
accommodation status reported were
parental home (41.6%) and private rented
accommodation (38.2%), with almost 85%
of participants residing in Dublin. There was
a varied level of education completed among
respondents with the most widespread levels
of education completed being lower
secondary (34.1%), higher secondary
(22.7%) and third level non-degree (20.5%).
Almost half of the participants (48.9%) were
currently unemployed and just under a fifth
(20.7%) were in full-time employment.
What are the motivations for PIED use
and the history of use?
Among the most prevalently reported
motivations for PIED use were to increase
muscle mass (91%), to increase strength
(75.3%), to look good (62.9%) and to
increase confidence (51.7%). Almost all
participants (96.6%) reported lifetime
injecting use of anabolic-androgenic steroids
(AAS), with the average age of initiation
being approximately 24 years old. The
youngest onset
of injecting use was sixteen years old and
the oldest was thirty-nine years.
Approximately 69% of participants reported
lifetime use of oral AAS. The average age of
initiation was approximately 23 years old,
with the age of first use ranging from 15-36
years. In terms of the trajectory of AAS use;
the most commonly reported sequence was
“starting using oral steroids and then
progressed to injecting steroids” (38%).
What is the nature of PIED use and
trends in PIEDs use?
There was a wide spread in terms of the
number of cycles of PIED use respondents
had undertaken over their lifetime. Just
under half of respondents were on either
their first cycle or second cycle of PIED use.
Almost a fifth of respondents had completed
five or more cycles (18%). The most
commonly reported length of usual cycle was
6-8 weeks (29.2%). However in just over
10% of cases, the length of usual cycle was
more than seventeen weeks. In terms of the
AAS being used; while respondents reported
current and past use of a wide variety of
AAS, Testosterone (single/multi esters) was
by far the most prevalently form of AAS used
during current cycles (84%) and previous
cycles (77.5%). Other commonly used AAS
previously/currently included Nandrolone
decanoate and Trenbolone acetate. In terms
of the use of ancillary compounds and post
cycle treatment drugs; the substances being
used most prevalently during current cycles
included Creatine (23.9%) and Aromatase
Inhibitors/Anti-Oestrogens (10.1%).
Substances which had been most commonly
used during previous cycles included
Creatine (37.5%), HCG (27.2%),
Clenbuterol (25.8%), Aromatase
Inhibitors/Anti-Oestrogens (24.7%), and
Clomiphene citrate (21.3%).
What are the side-effects experienced in
association with the use of PIEDs?
Participants described experiencng a broad
range of side-effects in association with their
use of PIEDs. Prominent side-effects which
had been previously experienced included
increased appetite (49.4%), increased sex
drive (46%), water rentention (44%),
increased aggression (38.2%), growth of
excessive body hair (36%), acne (36%),
sudden mood changes (31.5%), testicular
atrophy (29.2%), decreased sex drive
(33.7%), insomnia (23.6%), muscle/joint
pain (22.5%), anxiety (19.1%), and
depression (18%). Although cited with less
frequency, participants reported currently
experiencing a range of side-effects similar
to those above.
What are the patterns of poly-substance
use?
Participants reported the use a wide variety
of substances within their lifetime, with
alcohol (95.5%), tobacco (71.6%), cannabis
(68.2%), cocaine (56.8%), and
benzodiazepines (35.8%) showing the
highest levels of lifetime use. It is also
noteworthy that a small number of
participants reported having ever injected
heroin (11.4%), cocaine (5.7%), and new
psychoactive substances (2.3%). Recent use
(within the past month) of other substances
was also frequently reported. Again, alcohol
(62.5%), tobacco (52.3%), cannabis
(39.8%), benzodiazepines (22.7%), and
cocaine (17%) were the substances with the
most prevalent recent use.
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What is the training and exercise
profile?
Almost all participants reported that they
were engaged in a regular training and
exercise programme, with over 85% stating
that exercised four or more days a week. In
terms of type of training and exercise, 91%
of participants reported participation in
weight training and approximately 80% of
participants reported participation in
cardiovascular exercise. Approximately 46%
of participants reported participation in
organised sport, with the most prevalently
reported categories being bodybuilding
(15.7%), boxing (10.1%), and soccer
(10.1%).
What are the injecting practices?
The majority of respondents (55%) had
learned to inject from other PIED users,
while just over 30% of participants had
learned to inject either through a harm
reduction service or medical professional.
While intramuscular injection was the most
popular method of injection among
respondents, subcutaneous injection was
also reported. Injection in to the buttocks
was by far the most prevalently used site,
with deltoids and quadriceps being the next
most frequently used injecting sites.
Respondents had experienced a range of
injecting related injuries, with muscle pain
(47.5%) and bruising (37.5%) among the
most commonly cited. In terms of the
physical environment of injection; 80% of
respondents reported that they always
injected at home, whereas 2% reported that
they always injected at the gym. In terms of
the social environment of injection; over half
of the respondents always injected alone,
whereas 25% always injected with others. In
terms of the administration of injection; 71%
of respondents were always injected by
another person and 16% always injected
themselves. The majority of respondents
stated that they had never reused (84%),
lent (95%), or borrowed (98%) used needle
or syringes.
What are the levels of testing for blood-
borne viruses (BBVs), prevalence of
BBVs, and uptake of treatment for
BBVs?
While approximately a third of participants
had last been tested for HIV in the past 12
months, just under half of respondents had
never been tested. Of those respondents
who had been tested for HIV, there were no
reports of a positive status. Similar results
emerged concerning testing for Hepatitis C,
which again illustrated that while almost half
of respondents had never been tested,
approximately a third had been tested within
the past year. However, there were reports of
positive cases, with 4.6% of the overall
sample indicating that they had tested
positive for Hepatitis C. When framed in
terms of participants who had been tested
and knew their result; positive statuses
represented approximately 10% of
respondents. All participants who reported
being positive for Hepatitis C also had a past
history of injecting psychoactive drug use.
Results pertaining to the treatment status of
participants who had tested positive for
Hepatitis C indicated that they had either
completed treatment, were awaiting
treatment or further tests, or had declined
treatment. Just under half of participants had
ever been tested for Hepatitis B, with
approximately a third having last been tested
within 12 months. There were no reports of
a positive status for Hepatitis B and just over
a third of respondents had been vaccinated
against the virus.
What are PIED users’ perspectives on
harm reduction services?
Overall, participants described their
interaction with harm reduction services in
positive terms and articulated that services
were particularly useful for accessing sterile
injecting equipment and information relating
to PIED use. That being said, service users
also stated that the presence of users of
other psychoactive substances within harm
reduction services and needle exchanges
created an intimidating atmosphere, which
made them feel uncomfortable. In terms of
service provision, the primary desire
expressed by respondents was for a
separate, specialised service which catered
for their medical needs and was dedicated
exclusively to PIED use. Other suggestions
for service provision included having more
information on steroids, information available
in other languages, more advertisement of
the service, longer opening hours, and a
supervised injecting room.
Based on an evaluation of these findings in
the context of previous studies, a number of
key recommendations were proposed:
RECOMMENDATIONS FOR
PRACTICE
n As a group, users of PIEDs represent a
minority at harm reduction services. The
increasing prevalence of attendees, who
are using such substances, means that
harm reduction service providers, and
indeed drug and health services in the
wider context, should expect to interact
with this group. 
n PIED users are a diverse group of
individuals. Service providers should
anticipate diversity among attendees who
are users of PIEDs and endeavour to
provide accessible, inclusive and
culturally competent services, which
recognise the issues facing individuals. 
n The trend of users of PIEDs attending
harm reduction services is a relatively
new phenomenon and represents a
major transition in the client base of such
services. Professionals engaging with
PIED users face several challenges in
catering for the needs of this group, and
therefore, the provision of specialist
training and education is particularly
necessary. 
n Given the range of personal and public
health concerns associated with the use
of PIEDs, the need for harm reduction
approaches to be integrated within a
continuum of care is readily apparent.
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Interventions designed to minimise the
risk of harm should include the provision
of sterile injecting equipment, BBV
testing and vaccination, and health
services, as well as harm reduction
education and advice on BBV infections
and vaccinations, use of PIEDs,
associated side-effects, injecting
techniques, risk behaviours, diet and
training, use of other illicit substances,
and sexual health. 
n Existing harm reduction services are
traditionally geared towards users of
psychoactive substances. Given the
divergent profile and nature of substance
use among PIED users, there is a need
to develop a tailored approach in
response to the profile of harm within
this group. Expanding the range and
nature of models of practice may serve
to enhance accessibility, engagement,
and effectiveness. In particular, the
implementation and assessment of a
specialised PIED clinic on a trial basis
may be a beneficial development at this
time.
n The use of PIEDs is associated with a
wide range of adverse impacts, which
may manifest in physical, psychological,
and/or behavioural domains. The varied
needs of this group require integrative,
multi-disciplinary approaches to be
considered, with emphasis on developing
inter-agency links and establishing care
pathways between general health
services, harm reduction services, and
mental health services. 
RECOMMENDATIONS FOR
RESEARCH 
n The evidence base surrounding the
worldwide prevalence of PIED use is
gradually expanding. There is however a
deficit of knowledge surrounding the
epidemiology of use in an Irish context.
As such, population based surveys,
which examine the national prevalence of
use among adults and adolescents,
would shed light on the patterns of use
and provide a basis for policy-making
and planning. 
n The findings of the present study may
not be representative of the profile and
perspectives of users of PIEDs, who are
not attending harm reduction services.
Future research, which samples the
wider population of PIED users, would
provide a more comprehensive portrait. 
n Findings concerning BBVs in the present
study were based on self-report. In order
to ascertain a definitive prevalence,
future research which incorporates
serological testing is recommended. 
n In depth qualitative research would
provide a deeper understanding of the
experience and perspectives of PIED
users, and would further facilitate the
elicitation of their views regarding
appropriate service provision. 
n Future research exploring the
perspectives of healthcare and harm
reduction professionals would identify the
challenges associated with engaging with
PIED users and assess the feasibility of
developing integrative, multi-disciplinary
approaches. 
n Research surrounding the effectiveness
of existing harm reduction service
provision within an Irish context is
required to evaluate the capacity of
services to minimise the harms
associated with the use of PIEDs. 
n Service provision in Ireland, and indeed
internationally, appears to be hindered by
the lack of public health policies and
practice guidelines relating to the use of
PIEDs. Research in this area is essential
in order to inform policy and equip
services with the infrastructure and tools
necessary to provide effective
interventions. 
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THE FINDINGS OF THE PRESENT STUDY
MAY NOT BE REPRESENTATIVE OF THE
PROFILE AND PERSPECTIVES OF USERS
OF PIEDS, WHO ARE NOT ATTENDING
HARM REDUCTION SERVICES. 
T
he initial chapter of this study sets
out the contextual landscape which
underlies the present research. An
overview of the research problem is
presented and key concepts within the topic
of study are outlined. Following these
introductory sections, the extant empirical
literature surrounding harm reduction and the
use of performance and image enhancing
drugs (PIEDs) is explored. At the conclusion
of the chapter, the research context is
described and the specific research
questions of the present study are outlined.
1.1. OVERVIEW OF THE 
RESEARCH PROBLEM
During the course of the past three decades,
harm reduction approaches have gradually
emerged as a central pillar of international
drug strategies, and are currently endorsed
in policy or practice in approximately ninety-
seven countries and territories worldwide
(IHRA, 2012). Within the spectrum of harm
reduction services, needle and syringe
programmes (NSPs) play a significant role in
minimising harm arising from injecting drug
use (Wodak & Cooney, 2004). In recent
years, there has been a marked increase in
the prevalence of individuals attending NSPs
who are users of PIEDs. This trend has been
documented internationally (Iversen, Topp,
Wand, & Maher, 2013; McVeigh, Beynon, &
Bellis, 2003; Rich et al., 1999) and there are
noticeable indicators of a similar trend
emerging in an Irish context (Jennings,
2013; Robinson, Gibney, Keane, & Long,
2008). Although the level of harm associated
with the use of PIEDs is generally less overt
when compared to the risk associated with
the use of psychoactive substances (Aitken,
Delalande & Stanton, 2002; Day, Topp,
Iversen, & Maher, 2008), there are growing
concerns around the use of PIEDs and
related physical and psychological harms
(Evans-Brown & McVeigh, 2008; Hope et
al., 2013). Harm reduction services are
faced with several challenges in attempting
to respond to the expanding range of client
needs, and in spite of an anecdotal
awareness surrounding the increase of PIED
users accessing Irish services; there is a
paucity of empirical investigation addressing
this emerging trend.
1.2. DEFINING KEY CONCEPTS
As a prelude to exploring the context in
which the present study is engaged, an
examination of the key concepts is necessary
both to ground the focus of the study and to
specify the definitional position this research
adopts. As evidenced in the previous section,
the key concepts which underpin the present
study are performance and image enhancing
drugs and harm reduction.
1.2.1. Performance and Image Enhancing
Drugs. Within the literature surrounding the
non-medical use of substances which may be
used to enhance aesthetics and/or
performance, much of the research (e.g.,
Aitken et al., 2002, Midgley et al., 2000,
Peters, Copeland, & Dillon, 1999) has
conventionally focused on the use of anabolic-
androgenic steroids (AAS). Traditionally, such
substances were generally termed as
performance-enhancing drugs (PEDs), used
to describe the range of substances that could
have performance benefits for elite athletes
(Larance, Degenhardt, Dillon, & Copeland,
2005). While AAS remain the most
prominently used substances of this kind,
there is an increasing diversity in the
prevalence, profile, and motivations of
individuals who use AAS in conjunction with
related substances such as peptides, tanning
drugs, hormones, and weight loss agents
(Hope et al., 2013). To reflect these emerging
heterogeneous variables, much of the
contemporary literature incorporates umbrella
terms such as “performance and image
enhancing drugs” or “image and performance
enhancing drugs” (e.g., Dennington et al.
2008; Iversen, et al., 2013).
In an effort to encompass the diverse range
of substances, the breadth of associated
utilities, and the divergent motivations of
users, the current study adopts the term
performance and image enhancing drugs,
which is defined as substances that are used
to enhance performance (e.g. improving
strength and/or endurance), improve the
bodys appearance (e.g. increasing muscle
size and/or reducing body fat), mask the use
of performance-enhancing drugs to avoid
drug testing, and to manage the negative
side effects of substance use. Similar
definitions also appear in previous studies
(e.g., Dennington et al., 2008, Larance, et
al., 2005).
1.2.2. Harm Reduction. Emerging in the
early 1970s in response to the heightening
awareness around the public health concerns
related to substance use, harm reduction
represented a dramatic and controversial
paradigm shift in drug policy. While previous
models of addressing drug issues had
predominantly concentrated on prevention,
control and abstinence, harm reduction
approaches focus on minimising drug related
harm (Ritter & Cameron, 2005). Accordingly,
the philosophy of the harm reduction model
pragmatically accepts that drug use is a
prevailing reality and acknowledges the self-
determination of those who choose to use
drugs.
However, while the reduction of harm may be
delineated as the focal objective, the notions
of abstinence and harm reduction are not
considered mutually exclusive or
dichotomous extremes. Indeed,
contemporary visions of harm reduction
conceptualise it as a “combination
intervention” that is comprised of a variety of
interventions adapted to the diversity of
settings, systems and populations in which it
is operationalised (Rhodes & Hedrich,
2010). The present study draws from this
conceptualisation outlined by Rhodes and
Hedrich (2010; p. 19) and defines harm
reduction as “interventions, programmes and
policies that seek to reduce the health, social
and economic harms of drug use to
individuals, communities and societies”.
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Chapter 1: Review of  Literature
1.3. LITERATURE REVIEW
The adoption of harm reduction approaches
in Ireland emerged in the late 1980s,
whereby needle exchange programmes and
outreach services were introduced, in
response to the identification of persons who
inject drugs (PWIDs) as a high risk group for
contracting and transmitting blood-borne
viruses (BBVs) and the corresponding risk to
public and personal health (Butler, 1991).
Shortly thereafter, harm reduction
approaches were endorsed on a policy level
by the
Government Strategy to Prevent Drug
Misuse (1991) and have remained a
consistent feature of Irish drug policies for
more than two decades. Harm reduction
represented a primary pillar within the
National Drugs Strategy outlined in Building
on Experience 2001-2008 and is further
advocated in the National Drugs Strategy
(Interim) 2009-2016.
NSPs are recognised internationally and
domestically as a key component of
interventions designed to minimise drug
related harms and often act as the first point
of contact for drug users, facilitating initial
connection with drug services in a non-
judgmental interaction (Kuo et al., 2003).
Specifically, NSPs aim to engage with
PWIDs and attempt to limit the prevalence of
BBVs through the provision of sterile
injecting equipment, as well as offering
education around the risks associated with
drug use, providing access to health
services, and opening referral pathways in to
drug treatment (Cox & Robinson, 2008).
In the past, NSPs were traditionally geared
towards users of psychoactive substances
such as opiates. However, evidence from the
international literature indicates that users of
PIEDs appear to be an increasing subgroup
among NSP attendees. While this may not
necessarily be indicative of an overall
increase in use of PIEDs within the general
population, it does highlight the fact that a
considerable amount of individuals are using
these substances, and moreover, speaks to a
significant trend within the domain of harm
reduction (McVeigh et al., 2003). A recent
study based in Australia, highlighted that the
prevalence of PIED injectors attending NSPs
in Queensland and New South Wales rose
from 2.4% in 2010 to 4.6% in 2011
(Iversen et al., 2013). Evidence points to a
similar trend in the United States (e.g., see
Rich et al., 1999) and the United Kingdom,
where Evans-Brown & McVeigh (2008)
reported a 2000% increase in the number of
steroid injectors attending NSPs based in
Merseyside and Cheshire between 1991 and
2006. In Ireland, almost two-thirds of NSPs
have reported the presence of clients who
are injecting PIEDs (Robinson et al., 2008)
and a recent study in a Dublin based NSP
indicated that approximately 7% of a sample
of attendees were steroid users (Jennings,
2013). Overall, the results emanating from
international and domestic studies suggest
that although there is a substantial rise in the
prevalence of PIED users attending NSPs,
they remain a minority within the overall client
base. In light of their marginal profile, there is
the risk that the needs of this group are not
currently being wholly met in harm reduction
services (Larance, Degenhardt, Copeland, &
Dillon, 2008).
Viewed within a wider framework; PIED
users are also typically overlooked within
public health initiatives (Larance et al.,
2008). In an Irish context, while there has
been recent deliberation surrounding the
application of amended legislative controls
(Department of Health, 2013), there has
been little consideration afforded to the use
of PIEDs within any of the major Irish public
health policy documents such as the National
Drugs Strategy (Interim) 2009-2016, the
National Hepatitis C Strategy 2011-2014 or
the National Drug Rehabilitation
Implementation Committee protocols
(NDRIC; Doyle & Ivanovic, 2010). Given the
lack of current policy based
recommendations and the low coverage of
specialist service provision, there is the
indication that the developing trend
concerning PIED use in Ireland is being
relatively overlooked.
In addition, there is a severe paucity of
germane research relating to PIED use in
Ireland. However, looking to the wider
literature, there is a growing number of
international studies which have examined
the phenomenon of PIED use. Within the
following sections, the empirical research
surrounding users of PIEDs, with an
emphasis on a harm reduction perspective, is
reviewed in a number of areas: socio-
demographic characteristics of PIED users,
use of PIEDs, use of other substances,
injecting practices and BBVs, and the
interaction between PIED use and harm
reduction services.
1.3.1. Socio-demographic
characteristics. Traditionally, the non-
medical use of performance enhancing drugs
such as anabolic-androgenic steroids (AAS)
was primarily associated with elite athletes
and professional bodybuilders (Yesalis &
Bahrke, 1995). However, in the
contemporary landscape, elite athletes using
PIEDs to enhance performance represent a
small minority (Bahrke & Yesalis, 2004), with
most PIED users being recreational and non-
elite athletes whose motivations are geared
more towards increasing strength, building
muscle mass, and improving physical
appearance (Aitken et al., 2002; Cohen,
Collins, Darkes, & Gwartney, 2007). As
such, the socio-demographic profile of
individuals using PIEDs has become
increasingly diverse.
A synthesised summary of the variable of
age, in studies concerned with PIED use, is
portrayed in Table 1. Although this table does
not offer a comprehensive review of studies,
and does not include population/school
based surveys, it does provide a useful
overview of the previous findings concerning
the age of PIED users, particularly in the
context of harm reduction services. While in
some countries such as the United States,
Scandinavia, Australia and Canada there has
2 merchants Quay Ireland PIEDs Research
been considerable research attention and
public concern in relation to adolescent AAS
use, with some studies suggesting a higher
prevalence of use among adolescents when
compared to the general population (Dunn &
White, 2011; Pallesen, Josendal, Johnsen,
Larsen, & Molde, 2006), much of the wider
literature has focused on adult PIED users.
The selected studies in Table 1 highlight that
the age of participants across studies have
ranged from 17 to 79 years old, with the
average age of PIED users ranging from
twenty-seven to almost thirty three years old.
In terms of individuals accessing NSPs,
studies suggest that PIED users are more
likely to be younger when compared to other
populations of injecting drug users (Day et
al., 2008; Jennings, 2013).
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Median Age
25 years
27 years 
31 years
29 years 
—
—
28 years
—
—
TABLE 1
Overview of Age and Gender Variables in Studies of PIED Users
Study
Crampin et
al.,1998
Peters et al.,
1999
Aitken, et al.,
2002
Cohen et al.,
2007
Day et al., 2008
Larance et al.,
2008
Hope et al.,
2013
Jennings (2013)
Chandler &
McVeigh, 2014
Location
England and
Wales
Australia
Victoria,
Australia
United States
New South
Wales,
Australia
New South
Wales, Australia
England and
Wales
Ireland
United
Kingdom &
Ireland
Participants (gender)
149 AAS injectors (2 female) recruited
through Anonymous HIV Prevalence
Monitoring Survey self-completed
questionnaire
100 AAS users (6 female) recruited through
gyms, needle exchanges, & magazines
completed questionnaire (both self-report &
interview)
63 PIED injectors, (9 female) recruited from
Steroid Peer Education Program completed
questionnaire
1,955 (all male) adult non-medical AAS
users recruited online completed an internet
based survey
318 PIED injectors (12 female) recruited
from NSP Survey participants during the
years 1995 – 2004 self-completed
questionnaire
60 (all male) PIED users recruited through
advertisement completed face-face interview
395 (all male) PIED users recruited from
across 19 NSPs self-completed
questionnaire
25 (all male) AAS users sampled from NSP
attendees completed face-face questionnaire
94 PIED users (15 female) recruited through
online forums and NSPs completed an
internet based survey
Age Range
17 – 48 years
18 – 50 years
21 – 60 years
18 – 76 years
—
17 – 59 years
—
21 – 43 years
16 – 56 years
Mean Age
—
29.2 years
—
31.1 years
27 years
32 years
<25  27%
25-34 34%
≥35 27%
No report 12%
28.84 years
32.5 years
In terms of gender; research has consistently
demonstrated a significantly higher level of
PIED use among males. A recent global
epidemiological study estimated a lifetime
prevalence rate of AAS use of 6.4% for males
and 1.6% for females (Sagoe, Molde,
Andreaseen, Torsheim, & Pallesen, 2014).
Although there are variations in estimates, a
comparable pattern of elevated lifetime and
recent AAS usage amongst males have been
found internationally across population based
surveys (Australian Institute of Health and
Welfare, 2011; NACD, 2012), college student
surveys (Berning, Adams, Stamford, &
Finewman, 2004; McCabe, Brower, West,
Nelson, & Wechsler, 2007), and secondary
school based surveys (Dunn & White, 2011;
Hibell et al., 2011; Lorang, Callaghan,
Cummins, Achar, & Brown, 2011; Pallesen et
al., 2006). Table 1 illustrates that studies which
have recruited samples of PIED users through
online advertisement or education programmes,
have attracted an overwhelming majority of
male participants, and research within the
context of NSPs also show a vastly higher
concentration of male participants
(see “Participants” column in Table 1). A
number of studies have also demonstrated that
PIED users attending harm reduction services
are significantly more likely than other drug
using attendees to be male (Day et al., 2008;
Iversen et al., 2013). Given the convergence of
evidence noted above, the indicators suggest
that while a proportion of PIED users are
female, PIED use tends to be a predominantly
male phenomenon.
Additional socio-demographic variables of
interest in the domain of PIED use include
sexual orientation, occupation, level of
education, and socio-economic status. Sexual
orientation has received particular research
attention with a number of studies showing; as
much as one third of respondents being men
with a homosexual/bisexual orientation (e.g.
Larance et al., 2008; Peters et al., 1999), high
levels of AAS use among homosexual male
gym goers (Bolding, Sherr, & Elford, 2001),
and higher prevalence rate of lifetime AAS
misuse among adolescent homosexual/
bisexual boys when compared to their
heterosexual peers (Blashill & Safren, 2014). It
has been suggested that the basis of such
elevated prevalence of PIED use among sexual
minorities may be linked to an enhanced
emphasis on physical attractiveness and
increased body image concerns within some
sections of their culture (Larance et al., 2005).
Occupation has also been proposed as an
influential socio-demographic variable, with the
suggestion that PIED use may be perceived as
beneficial in the execution of employment
duties among certain occupations such as
security personnel, door staff, fitness
consultants, actors, bodyguards, fire fighters,
and members of the armed forces (Maycock,
1999; Monaghan, 2002; Peters et al., 1999).
Qualitative findings have described that while
occupation may have a bearing on underlying
motives; it is not an isolated factor, with PIED
use in these cases stemming from a
confluence of personal and occupational
motivations (Dennington et al., 2008).
Thus, it has been put forth that the majority of
PIED users are generally concerned with
improving both their physical appearance and
functioning (Peters et al., 1999).
In terms of level of education and socio-
economic characteristics, a number of studies
have found PIED users to be well-educated
professionals, with samples showing high rates
of employment and above average levels of
income (Cohen et al., 2007; Dennington et al.,
2008; Peter et al., 1999). However, alternative
studies have reported variables such as
relatively high level of recent involvement in
crime (Larance et al., 2008). Such seeming
incongruity is reflective of the general
heterogeneity apparent in the socio-
demographic profile of users of PIEDs across
studies, and implies that although key socio-
demographic characteristics such as gender,
age, sexual orientation, occupation, level of
education, and socio-economic status are
useful markers, it is difficult to typify such a
diverse group.
1.3.2. Use of PIEDs. Heightened awareness
around the increasing prevalence of PIED use
among a wider population within recent
decades had led to the emergence of a
significant evidence base exploring why
individuals use, what the trajectory of use is,
what substances are used, and how
substances are used.
A recent synthesis of the body of qualitative
research concerning the aetiology of AAS use
summarised that factors such as participation in
sports, maladaptive relationships,
psychopathology, negative self and body
image, deviant behaviour, and abuse of other
drugs, were prominent features of users prior
to initiation (Sagoe, Andreassen, & Pallesen,
2014). In terms of when adult users
commence PIED use; single studies have
found average age of initiation to be 25.1 years
old (Peters et al., 1999), 25.8 years old
(Cohen et al., 2007), and 24 years old
(Larance et al., 2008), which would appear to
support the epidemiological evidence that has
estimated that approximately 80% of AAS
users initiate use before the age of 30 years
old (Pope et al., 2014).
Within the literature, much attention had been
paid to the question of why individuals choose
to use PIEDs, with users typically delineated in
to three broad categories based on underlying
motivation for use (e.g., see Evans-Brown &
McVeigh 2008; Peters et al., 1999). These
groupings of users have included professional
athletes (those who use in order to enhance
performance), occupational users (those who
use in order to support/enhance occupational
functioning), and body image users (those who
use in order to improve physical aesthetic).
Quantitative studies which have examined
individuals motives report a range of
motivations such as to improve physical
appearance, to become stronger, to increase
size, to enhance performance, to increase
confidence, to decrease fat, and/or to improve
mood (Aitken et al., 2002; Cohen et al.,
2007). While motivations described within the
qualitative literature support these principal
motives, there is the indication that a further
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range of more nuanced psychosocial elements
including psychological well-being, family/peer
influence, social status, and social norms, may
also play a role in motivating and maintaining
PIED use (Dennington et al., 2008; Sagoe, et
al., 2014).
With regard to what substances are prevalently
used; Larance and colleagues (2005) detail
that PIEDs refer to a range of substances
which are generally used to enhance muscle
growth (anabolic effects) and/or to reduce
body fat (catabolic effects). Within the
spectrum of these substances, AAS (a group
of drugs which include testosterone, the male
hormone, as well as several synthetic
derivatives, which imitate male sex hormones)
are the most prominently used, and widely
investigated, form of PIEDs (Larance et al.,
2005; Pope, & Bower, 2009). Such
substances may have anabolic effects
(promoting the development of muscle growth)
and/or androgenic effects (promoting the
development of male sex characteristics such
as body hair, deepening of voice, development
of male sex organs and sex drive). While the
available evidence suggests that all forms of
AAS possess both anabolic and androgenic
properties, there are variances in ratio of these
properties between different types of AAS
(Larance et al., 2005).
Table 2 provides an overview of common types
of AAS and illustrates the route of
administration and primary effect of each type.
While few empirical studies have detailed
patterns of specific AAS use, Cohen and
colleagues (2007) found that within their large
sample of male adult PIED users, single ester
testosterones (78.2%), methandrostenolone
(64.9%), and nandrolone decanoate (63.5%),
multi ester testosterones (56%), and stanozolol
(56%) were the most commonly used agents.
The available evidence also suggests that the
use of injectable forms of AAS is generally
more prevalent than the use of oral compounds
(Hope et al., 2013; Larance et al., 2008).
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Chemical Name
Boldenone undecyclenate
Chlorodehydromethyltestosterone
Drostanolone Propionate
Fluoxymesterone
Formebolone
Mesterolone
Methandrostenolone
Methenolone Enanthate
Nandrolone decanoate
Nandrolone laurate
Nandrolone undecanoate
Oxandrolone
Oxymetholone
Stanozolol
Testosterone Suspension, Esters &
Blends (e.g. Cypionate, Propionate,
Suspension, Undecanoate)
Trenbolone acetate
Trenbolone hexahydrobencylcarbonate
Brand Name(s)
Equipoise, Boldebal
Turinabol, Turanabol
Masteron
Halotestin
Esiclene
Proviron
Dianabol, Anabol,
Metanabol, Naposim
Primobolan
Deca Durabolin,
Extraboline
Laurabolin
Dynabolon
Anavar
Anadrol, Anapolon
Winstrol, Stromba
Testa C, Testoviron
Sustanon, Andriol
Trenbolone, Finaplix
Parabolan
Administration
Injection
Oral
Injection
Oral
Injection
Oral
Primarily oral but also
injectable forms
Injection
Injection
Injection
Injection
Oral
Oral
Oral & Injection
Injection
Injection, Transdermal & Nasal
Injection
Description
Primarily Anabolic
Primarily Anabolic
Primarily Anabolic
Primarily Anabolic
Primarily Anabolic
Primarily Androgenic
Primarily Anabolic (w
androgenic properties)
Primarily Anabolic
Primarily Anabolic
(moderately androgenic)
Primarily Anabolic
Primarily Anabolic
Primarily Anabolic
Primarily Anabolic
Primarily Anabolic
Primarily Anabolic
(different varieties of
testosterone)
Primarily Anabolic
Primarily Anabolic
Note. Adapted from “Performance Enhancing Drugs Resource Pack” by K. Flemen, 2011.
TABLE 2
Overview of Common Types of AAS
The use of AAS has been associated with a
host of adverse side-effects. Several authors
have reviewed the evidence regarding these
associated effects (e.g. Bahrke & Yesalis,
2004; Kanayama, Hudson, & Pope Jr.,
2008, 2010; van Amsterdam, 2010), which
are illustrated in Table 3. In spite of the
evidence which indicates that AAS use may
be associated with such adverse health
effects, it should be noted that the
knowledge base surrounding the prevalence
and magnitude of these short-term and long-
term effects is limited (Kanayama, et al.,
2008). In particular, a consistent causal link
between AAS use and the majority of
adverse effects has not been well
established, and related investigation in to
health effects is confounded by the diversity
of variables such as the range of AAS
substances used, dose, frequency, age of
initiation, period of use, and use of other illicit
substances (Bahrke & Yesalis, 2004). As
such, several authors have suggested that
the dangers of AAS use are generally
overstated (Cohen et al., 2007; Evans,
2004). That being said, AAS users within the
empirical literature typically report
experiencing side-effects (Larance et al.,
2005). Given the recent proliferation of use
and the lack of longitudinal studies, it may be
the case that the adverse public health
consequences of long-term AAS use are
being underestimated rather than
overestimated (Kanayama et al., 2008).
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Cardiovascular effects Hypertension (elevated blood pressure) Cardiomyopathy (heart disease)
Myocardial hypertrophy (enlargement of the heart)
Myocardial ischemia (decreased blood flow to heart due to blockage of arteries) Dyslipidemia (decreased high
density lipoprotein and increased low density lipoprotein) Arrhythmia (irregular heartbeat)
Thrombosis (blood clotting)
Hepatic effects Jaundice
Peliosis hepatis (development of multiple blood-filled cystic spaces in the liver)
Hepatocellular hyperplasia (abnormal multiplication of cells in the liver)
Hepatocellular adenomas (benign tumours in the liver)
Dermatologic effects Acne
Stretch marks
Alopecia (hair loss)
Psychological effects Depressive symptoms
Hypomania/mania
Dependence
Personality disturbances
Other psychiatric disorders
Behavioural effects Increased aggression/violence
Male–specific effects Gynaecomastia (abnormal enlargement of the male breast tissue)
Changes in the male reproduction systems (which may include reduction in levels ofendogenous testosterone,
testicular atrophy, reduction in sperm count and spermmotility, and alterations in sperm morphology)
Female-specific effects Menstrual abnormalities
Deepening of the voice
Shrinkage of the breasts
Increase in clitoris size
THE USE OF 
AAS HAS BEEN
ASSOCIATED 
WITH A HOST 
OF ADVERSE 
SIDE-EFFECTS
TABLE 3
Overview of Adverse Effects Associated with the Use of AAS
While a number of the aforementioned side-
effects may be permanent, some effects
may be experienced temporarily whilst using
AAS (Larance et al., 2005). As such, the
nature of AAS use is typically cyclical,
whereby users undertake periods of use,
interspersed with periods of non-use,
designed to facilitate the endocrine systems
of the body to return to homeostasis (Cohen
et al., 2007). Although there is little empirical
clinical evidence supporting the notion that
the practice of cycling may reduce the risk of
adverse effects, or indicating ideal cycle
length, users are generally guided by
anecdotal evidence generated by previous
experience, internet forums, or information
websites (Chandler & McVeigh, 2014).
Studies which have examined cycling show
users differ significantly in the length of their
cycles. An example of this variability is
indicated in Cohen and colleagues (2007)
wherein participants cycle length ranged
from 1 week to 728 weeks, with a median
length of 11 weeks. This median length
appears to be relatively consistent with that
found in other studies (e.g., see Aitken et al.,
2002; Larance et al., 2008).
Within this cycle of substance use, typical
patterns suggest that in addition to AAS,
PIED users may also use a number of
ancillary compounds and/or post cycle
treatment drugs. An overview of the range of
common auxiliary substances is outlined in
Table 4. Such substances may be used in
order to achieve anabolic or catabolic effects
and/or minimise potential adverse side-
effects. Studies show that although these
substances appear to be used less
prevalently than AAS, there is significant use
of other hormones (e.g. human growth
hormone), beta agonists (e.g. clenbuterol),
stimulants (e.g. ephedrine), drugs for weight
loss (diuretics), drugs believed to stimulate
testosterone (e.g. clomiphene), and agents
used to counteract unwanted physical side-
effects (e.g. tamoxifen) among AAS users
(e.g., see Chandler & McVeigh, 2014;
Cohen et al., 2007; Hope et al., 2014;
Larance et al., 2008).
In short, the features underlying the use of
PIEDs appear to an interconnected set of
nuanced psychological, social, behavioural,
and physical factors, with the predominant
conscious motivations for use revolving
around the size, shape, and performance of
the body. Initiation of use typically occurs in
the mid-twenties, with individuals using
multiple steroids and ancillary substances in
a cyclical fashion, with significant levels of
injecting use occurring within this regime. A
definitive portrait of the side-effects related
to PIED use remains relatively unclear but
users frequently report experiencing adverse
health effects.
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A DEFINITIVE PORTRAIT OF THE 
SIDE-EFFECTS RELATED TO PIED USE
REMAINS RELATIVELY UNCLEAR BUT USERS
FREQUENTLY REPORT EXPERIENCING
ADVERSE HEALTH EFFECTS.
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PIED Related Use
Used to block or inhibit the actions of oestrogen,and
reduce risk of feminisation
Used to stimulate production of testosterone inmen and
reduces risk of testicular atrophy
Used to trigger natural testosterone production
A synthetic compound of naturally occurringhormone
with strong anabolic effects
A stabilised analogue of the growth hormone-releasing
factor (GRF), used to build leanmuscle while burning
excess fat
Pancreatic hormone which regulates blood-sugarlevels
used to increase the amount of glycogentransported to
muscles
An analogue of the liver-produced substanceInsulin
Growth Factor, primarily used toincrease burning of fat
Medication used to treat thyroid insufficiency,used to
increase metabolism and burn fat
A beta-2 agonist used as a stimulant to aid fatburning
and muscle definition
A stimulant used to speed up metabolism and burn fat
Used to increase amount of melanin produced
Used to help reduce water retention and increasemuscle
hardness and definition
Used to delay fatigue and aid recovery
A mixture of fatty acids, alcohol and lidocainewhich
causes muscles to swell
Used to prevent or treat acne
Sedative/relaxant used to promote sleep and tostimulate
natural production of growth hormone
Chemical Name
Aromatase Inhibitors/Anti-
Oestrogens (e.g. Anastrozole,
Exemestane)
Human Chorionic Gonadotrophin
(HCG)
Clomiphene citrate
Human Growth Hormone (HGH)
Growth Hormone Fragment
Insulin
Insulin Growth Factor (IGF)
Thyroid Agents
Clenbuterol
Ephedrine
Tanning Agents
Diuretics
Creatine
Synthol
Anti-acne medication
Gammahydroxybutyrate (GHB)
Brand Name(s)
Tamoxifen,
Arimidex,
Letrozole
Clomid
Somatropin
Humulin R
Somatomedin C
Thyroxin,
Cytomel
Spiropent
Melanotan,
Epitan
Aldactone,
Lasix
Accutane
Administration
Oral
Injected
Oral
Injected
Inject
Injected
Injected
Oral
Oral
Oral
Injected
Oral
Oral
Injected
Oral
Oral
TABLE 4
Overview of Common Ancillary Compounds/Post Cycle Treatment Drugs
Note. Adapted from “Performance Enhancing Drugs Resource Pack” by K. Flemen, 2011.
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1.3.3. Use of other substances. In
addition to examining the use of AAS and
ancilliary compounds, previous research has
also investigated the levels of polydrug use
among PIED users. Table 5 provides an
illustrative example of the prevalence of use
of other substances found in selected
previous studies. Within the study by Peters
and colleagues (1999), 14% of participants
had ever injected an illicit substance other
than AAS, whereas 27% of participants in
the study from Larance and colleagues
(2008) reported having ever injected other
illicit drugs. However, a comparative study
conducted in Australia with a small sample
found no significant difference between AAS
users and non-users regarding use of illicit
substances in the past six months (Dunn,
2009). Within a recent Irish study concerning
attendees at a Dublin based harm reduction
service, 40% of AAS users sampled
reported use of at least one other illicit drug
within the past month (Jennings, 2013). In
combination, while the results of the
aforementioned studies suggest that a
relatively high proportion of users of PIEDs
also use other illicit substances, it remains
unclear whether this pattern of polydrug use
is within a problematic range.
Drug Type Lifetime Ever Injected Recent Use
Use (%) (%) (%)^*
Marijuana 70 - 17
Amphetamines 51 6 11
Ecstasy 49 3 18
Cocaine 43 4 5
Hallucinogens 36 - -
Inhalants 20 - 4
Heroin 9 5 1
Methadone 2 1 -
Cannabis 80 0 50
Methamphetamine powder 78 20 31
Crystal methamphetamine 53 17 28
Ecstasy 77 8 56
Cocaine 75 13 40
Heroin 17 12 10
Inhalants 45 0 15
Benzodiazepines 8 2 8
Hallucinogens 45 5 3
TABLE 5
Overview of Studies Concerning Polydrug Use Among PIED Users
Study
Peters et
al., 1999
Larance et
al., 2008
Location
Australia
Australia
Participants
100 AAS
users (6
female)
recruited
through
gyms,
needle
exchanges,
magazines
60 male
PIED users
recruited
through
adverts
^ In Peters et al., 1999 “recent use” was defined as one or more times per month
* In Larance et al., 2008 “recent use” was defined as use in the last 6 months 
1.3.4. Injecting practices and blood-
borne viruses. Evidence from international
studies highlights that a high volume of PIED
users are injecting substances (e.g. see;
Cohen et al., 2007; Hope et al., 2013;
Larance et al., 2008). The World Health
Organisation (WHO; 2010, 2012) outline
that injecting drug use (IDU) has been
consistently linked with the risk of blood-
borne viruses (BBVs) such as human
immunodeficiency virus (HIV), hepatitis C
virus (HCV) and hepatitis B virus (HBV).
Research over the past two decades has
detailed that injecting risk behaviours, such
as sharing of injecting equipment and
paraphernalia, as the principal mechanism of
contracting and transmitting BBVs (Cox &
Robinson, 2008). Furthermore, IDU is
associated with a number of additional health
consequences such as bacterial infections,
vascular damage and abscesses (Health
Protection Agency, 2012). Traditionally,
much of the attention around the risks of
IDU has focused on persons who inject
psychoactive drugs but given the increasing
prevalence of PIED use, there are
heightening concerns around the potential
for BBV transmission and injecting related
injuries among PIED injectors.
Looking to the literature, research has
consistently found that when compared to
psychoactive drug injectors, PIED users
engage in a much lower rate of injecting risk
behaviours such as borrowing, lending or
reusing used injecting equipment, or injecting
with other people (Aitken et al., 2002;
Cohen et al., 2007; Crampin et al., 1998;
Day et al., 2008; Hope et al., 2013;
Larance et al., 2008). Possible factors
underlying this lower level of risk behaviours
may include the lack of craving for AAS, the
lower risk associated with intramuscular
injection, and less frequent injection (Midgley
et al., 2000). Given the long established link
between injecting risk behaviours and the
spread of BBVs, the safer injecting
behaviours practiced by PIED users may
underlie the comparatively low prevalence of
BBVs among PIED users.
While there has been limited research
concerning rates of BBVs among PIED
users in Ireland, international studies have
found the prevalence to be much lower than
that typically found among those who inject
psychoactive drugs. Table 6 provides a
summary of international studies which have
assessed BBV prevalence among PIED
users. In Australia, studies which have
employed serological testing have found no
evidence of HIV (Aitken, et al., 2002; Day et
al., 2008). Conversely, in a study which
incorporated self-report measures, a rate of
12% HIV was found (Larance et al., 2008).
Rates of HCV found in the aforementioned
Australian studies ranged from 5-10% and
rates of HBV ranged from 3-12%.
A small number of studies have been
conducted in the UK, with a recent study
from Hope and colleagues (2013) finding
seroprevalence rates of HIV (1.5%), HCV
(5.5%), and HBV (8.8%). Such results
suggested that although BBVs remained
relatively low, it indicated an elevated
prevalence of HIV and HBV compared to
previous research (Crampin et al., 1998) in a
UK context. It is however noteworthy that
within these studies, the positive cases of
BBVs found were often associated with
factors such as a bisexual or homosexual
orientation, incarceration, injecting
psychoactive drug use, and number of
tattoos. As such, it is difficult to ascertain
whether contraction of BBVs was a
consequence of injecting PIED use. A further
complication in attempting to extrapolate
BBV prevalence among PIED users may be
that users are less likely to get screened
(Day et al., 2008). Given the high prevalence
of injecting PIED use, coupled with the risk
factor for BBVs, the apparent lack of
screening access/uptake, and the potential
for injecting related injuries; the importance
of harm reduction services engaging with
PIED users has been emphasised across a
number of studies (Hope et al., 2013;
Larance et al., 2008).
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HIV
0%
0%
0%
12%
1.5%
HBV
2%
12%
N/A
3%
8.8%
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Factors Associated with Positive Status
—
HCV associated with heroin injection,
imprisonment, sharing needles to inject other
drugs, no. of tattoos, and HBV exposure.
HBV associated with hepatitis C virus
exposure, past imprisonment and age of first
injection
HCV associated with homo/bisexual
orientation and a history of tattooing.
All HIV were bisexual or homosexual
orientation. HBV positive self-reports were
associated with HIV positive self-reports. 
HCV associated with having ever injected
other illicit drugs and lifetime use of heroin.
HIV associated with having male sexual
partners, having sought advice from STI
clinic, having abscess/open wound at
injection site.
HCV associated with having ever injected
psychoactive drug/having taken a
phosphodiesterase type 5 inhibitor in the
preceding year. 
HBV associated with having obtained advice
from an SH/STI clinic and having not injected
oneself subcutaneously in the preceding year.
Study
Crampin et
al., 1998
Aitken, et
al., 2002
Day et al.,
2008
Larance et
al., 2008
Hope et
al., 2013
Location
England
and Wales
Victoria,
Australia
New
South
Wales,
Australia
New
South
Wales,
Australia
England
and Wales
Participants
149 AAS
injectors
recruited
through HIV
Prevalence
Monitoring
Survey
63 PIED
injectors
recruited from
Steroid Peer
Education
Program
318 PIED
injectors
recruited from
NSP Survey
participants
during the years
1995 –2004
60 PIED users
recruited
through
advertisement
395 PIED users
recruited from
across 19 NSPs
Test Type
Biological
testing
Biological
testing
Biological
testing
Self-report
Biological
testing
HCV
—
9.5%
10%
5%
5.5%
TABLE 6
Overview of Studies of Blood-borne Virus Prevalence Among PIED Users
1.3.5. The interaction of harm reduction
and users of PIEDs. Given the furtive
nature of PIED use, users are reluctant to
seek medical treatment and furthermore,
they often lack trust in health care
professionals (Chandler & McVeigh, 2014;
Dunn, 2002; Pope, Kanayama, Ionescu-
Pioggia, & Hudson, 2004). Thus, the main
agencies which are likely to maintain regular
contact with this group are NSPs (Larance et
al., 2008). The evidence indicates that NSPs
in many regions are providing services to
PIED users (Day et al., 2008; McVeigh et
al., 2003; Rich et al., 1999; Robinson et al.,
2008). That being said, the relatively sudden
influx of a client group whose characteristics,
range of substance use, and injecting
practices differ significantly from the
traditional client base means that harm
reduction service providers are faced with
several challenges in attempting to respond
to the corresponding shift in client needs.
Such challenges are manifest in a recent
study from Dunn and colleagues (2014),
which explored the perspectives of staff
working in NSPs with regard to providing
services to steroid users. In particular,
workers described the difficulty in acquiring
specialised knowledge around the nature and
effects of PIED use, associated injecting
practices, and the provision of appropriate
injecting equipment. Accordingly, a common
recommendation proposed within the
literature is for the provision of specialist
training and education for NSP workers
(Dunn, McKay, & Iversen, 2014; Iversen et
al., 2013).
The wider recommendations emanating from
studies concerning harm reduction and PIED
users emphasise the need for further service
development and support a targeted
intervention for this group. In terms of the
requirements of PIED users, research has
advocated the need for education and harm
reduction advice around BBV infections,
vaccinations, injecting techniques, risk
behaviours, dose and frequency of PIED
use, adverse physical effects associated with
PIED use, diet and training, use of other illicit
substances, sexual health, and the
importance of monitoring physical and
psychological health, as well as access to
sterile injecting equipment, BBV testing,
HBV vaccination, and sexual health services
(Aitken et al., 2002; Hope at al., 2013;
Iversen et al., 2013; Larance et al., 2008).
However, in reality, there is a high level of
variability in the delivery of harm reduction
programmes for PIED users across services,
which highlights the lack of best practice
policy guidelines (Kimergård & McVeigh,
2014),
A number of additional concerns are evident
in attempting to apply existing programmes
of harm reduction as a method of
intervention for PIED users. This group do
not perceive themselves as
„drug users, and therefore, the stigma
associated with conventional drug services,
such as NSPs, is likely to impede service
uptake and reduce engagement amongst
PIED users (Dunn et al., 2014; Kimergård &
McVeigh, 2014; Simmonds & Coomber,
2009). The manner in which PIED users
typically utilise services would appear to
support this assertion, as although the
majority of clients who attend NSPs obtain
injecting equipment, few appear to use these
services for seeking information (Larance et
al., 2008). Further concerns, which have
been discussed by service providers within
the literature, include the extent of the
boundaries around interventions for PIED
users (e.g. whether or not to provide
information on specific types of AAS), and
indeed, whether harm reduction services
should cater for PIED users at all as
resourcing their needs shifts funding and
focus away from the traditional client base
(Dunn et al., 2014; Kimergård & McVeigh,
2014). In the effort to address the
aforementioned concerns and enhance the
interaction between PIED users and harm
reduction, a small number of specialist,
steroid-specific services, have been
implemented in the United Kingdom and
Australia. While such programmes appear to
show potential, there remains limited
empirical evaluation of their effectiveness in
minimising harm (Kimergård & McVeigh,
2014).
1.4. THE PRESENT STUDY
The literature has highlighted the growing
incidence of users of PIEDs accessing harm
reduction services, the diverse profile and
harm reduction needs of this group, and the
challenges faced by public health initiatives
and service providers in responding to this
emerging trend. Given the lack of previous
research in an Irish context, there exists a
need to develop an evidence base which
explores the profile of PIED users and their
perspectives on Irish harm reduction
services, in order to inform interventions
which aim to address the risk of harm within
this group.
1.4.1. Research context. The present
study is being conducted in conjunction with
Merchants Quay Ireland (see www.mqi.ie),
an Irish based organisation which offers a
variety of services for individuals who are
homeless and /or drug users. Within the
spectrum of facilities offered, MQI Day
Services provide frontline drug services. A
cornerstone of the drug service is the Health
Promotion Unit - Needle Exchange. The
main objectives of the Health Promotion Unit
are concerned with minimising the harms
associated with drug use and educating drug
users on the potential risks. Accordingly, the
primary focus is on HIV and Hepatitis
prevention, promoting safer injecting
behaviours and techniques, providing
information on associated risks and offering
drug users a pathway in to treatment. 
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1.4.2. Research questions. The present
study aims to examine the profile and
perspectives of users of PIEDs accessing
Irish based harm reduction services.
Accordingly, the research is focused on the
PIED using client base of services, with the
specific research questions being: 
n What is the socio-demographic profile? 
n What are the motivations for PIED use
and the history of use? 
n What is the nature of PIED use and
trends in PIEDs use? 
n What are the side-effects experienced in
association with use of PIEDs? 
n What are the patterns of poly-substance
use? 
n What is the training and exercise profile? 
n What are the injecting practices? 
n What are the levels of testing for BBVs,
prevalence of BBVs, and uptake of
treatment for BBVs? 
n What are PIED users perspectives on
harm reduction services? 
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T
his chapter describes the specific
methodology incorporated in the
present study. An outline of the
research design and the corresponding
rationale is included, as well as information
relating to the sampling and characteristics of
the participants. In addition, the chapter
provides a description of the materials used,
the procedure of data collection, and the
method of data analysis. In the concluding
section, the ethical issues associated with
the study, and the steps taken to address
these, are also presented.
2.1. RESEARCH DESIGN
A mixed method research design was
employed in the present study. A mixed
method approach is focused on the collection,
analysis, and mixing of both quantitative and
qualitative data, with an underlying principle
that the use of quantitative and qualitative
approaches in concert facilitates a more in
depth understanding of the research problem
than the use of either approach exclusively
(Creswell & Plano-Clark, 2011). Johnson and
Onwuegbuzie (2004) assert that research
approaches should be blended in a manner
which affords the best opportunities for
achieving important research objectives. Given
that the present study aimed to examine the
profile of PIED users accessing harm
reduction services, while concurrently eliciting
their perspectives on harm reduction service
provision, a mixed method research paradigm
was considered to be the optimal fit.
2.2. PARTICIPANTS AND SAMPLING
Purposive sampling (e.g. see, Teddlie &
Tashakkori, 2009) was utilised for the
present study in order to identify individuals
attending harm reduction services, who were
users of PIEDs. The sample was drawn from
clients presenting to harm reduction services
in Ireland. Staff at Merchants Quay Ireland
(MQI) Day Services, which are primarily
based in Dublin, were asked to identify
attendees who were current PIED users and
participants were recruited through the
organisation. The sample consisted of 89
participants, all of whom were male. The age
of participants ranged from 18-40 years
(M=26.91, Mdn=26, SD=5.87). Eighteen
participants were currently on their first cycle
of PIEDs usage, and 71 participants had
completed at least one cycle of PIEDs use.
2.3. MATERIALS
A mixed method questionnaire was
developed for the purposes of data
collection. Items included within the
questionnaire were informed by the extant
literature surrounding PIED use and injecting
drug use (e.g., van Amsterdam et al., 2010,
Brunsdon, 2010, Flemen, 2011,
Hildebrandt, Langenbucher, Lai, Loeb, &
Hollander, 2011, Jennings, 2013, Peters,
Copeland, & Dillion, 1999). The
questionnaire included nine sections which
focused on: socio-demographic
characteristics (age, gender, nationality,
sexual orientation, ethnic background,
county/type of residence, occupation,
employment status, level of education), use
of PIEDs (use of AAS, use of ancillary
compounds and post-cycle substances,
nature of use, history of use, motivation for
use), side-effects experienced in association
with PIED use (either during, post, or
between cycles), use of other substances
(substance use, history of use, route of
administration), training and exercise (nature
and intensity), injecting practices (method,
site, related injuries, environment, risk
behaviours), blood-borne viruses (testing,
status, and treatment), harm reduction
service utilisation (attendance, motivation)
and perspectives on harm reduction services
(experience of services, suggestions for
service provision, general commentary).
2.4. PROCEDURE
A pilot study was conducted with two
participants in order to examine elements
involved in the research process. Following
this pilot study, issues around the materials,
procedure, and logistics were discussed and
refined. Data collection for the main study
took place over a period of 8 weeks. Clients
presenting to MQI harm reduction services,
who were users of PIEDs, were invited to
participate in the research study. Information
sheets, which outlined the nature, purpose,
and conditions of the study, were provided
to all potential participants. Written consent
was obtained from individuals who decided
to take part in the study. Data collection was
conducted within the needle exchange,
safer injecting, and outreach departments of
the health promotion unit in MQI Day
Services. Participants were offered the
questionnaire, prompted to read the
instructions, and given the opportunity to
ask questions. Participants then self-
completed the instrument. The average time
for completion for the questionnaire was
approximately 15-20 minutes and all
questionnaires were completed in the
presence of a member of the research
team. In any instances where participants
had issues around literacy or language
diversity, data administrators assisted them
in filling out the questionnaire. In this
scenario, data administrators were
instructed to avoid asking participants
leading questions or influencing responses.
2.5. DATA ANALYSIS
Analyses of quantitative data were primarily
descriptive in nature, with appropriate
statistical data analyses carried out using
the Statistical Package for the Social
Sciences (SPSS; V.20.). Prior to analysis,
missing responses were identified and
coded. The results presented herein are
adjusted for these missing data. Qualitative
data were analysed using the inductive
thematic analysis framework described by
Braun and Clark (2006): data were
transcribed verbatim; coded in a systematic
fashion and collated in to initial themes;
themes were reviewed and checked in
relation to the coded extracts; a formative
inter-rater reliability check was conducted,
with a consensus-percent of 76% reached;
following discussion around problematic
themes, a number of elements were refined;
and finally themes were defined. In order to
assess reliability of the findings, a
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summative inter-rater reliability check was
conducted, which showed an overall
consensus level of approximately 92%. All
qualitative data analyses were completed
manually.
2.6. ETHICAL CONSIDERATIONS
A number of ethical issues presented within
the current study. In order to address issues
around informed consent; an information
sheet was provided to all participants to
ensure that they were fully aware of the
nature of the study and the terms of
participation. Within this information sheet, it
was also emphasised that participation was
completely voluntary, and non-participation
would not negatively impact their relationship
with MQI in any way. Participants were also
made aware that all information provided was
confidential and would be used in a published
research study. Written consent was obtained
from all participants to document that they
understood the conditions of the study and
agreed to participate voluntarily. Additionally,
participants were encouraged to ask
questions at all stages during the research
process. Due to the nature of the research
and the content of the questionnaire, the data
collection process included the potential for
sensitive data to be elicited. In order to
address issues around sensitivity, training
around the collection of sensitive data was
provided to all administrators, and aftercare
protocols, such as the provision of on-site
counselling and medical services, were
implemented.
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WITHIN THIS INFORMATION SHEET, IT
WAS ALSO EMPHASISED THAT
PARTICIPATION WAS COMPLETELY
VOLUNTARY, AND NON-PARTICIPATION
WOULD NOT NEGATIVELY IMPACT THEIR
RELATIONSHIP WITH MQI IN ANY WAY.
T
he aim of the present study was to
examine the profile and perspectives
of individuals accessing harm
reduction services who are users of PIEDs.
Data collected consisted of participantsself-
reported responses on a mixed method
questionnaire. Quantitative data included
socio-demographic characteristics, use of
PIEDs, side-effects experienced in
association with use of PIEDs, training and
exercise, use of other substances, injecting
practices, blood-borne viruses, and harm
reduction service utilisation. Qualitative data
were comprised of participants  perspectives
on harm reduction services. Within this
chapter, results gleaned from quantitative
analyses are presented at the outset, and are
then followed by a description of the
qualitative findings.
3.1. DESCRIPTIVE STATISTICS
The descriptive statistics for the total sample
are illustrated in Table 7. Eighty-nine
participants took part in the study and all
participants were male. Significantly, no
female clients, who were users of PIED,
presented to services during the period of
data collection. The age of participants
ranged from 18-40 years old, with the
average age being approximately 27 years
old (M=26.91, Mdn=26, SD=5.87). In
further delineating the age profile;
approximately 38% of participants were
aged 18-24 years old, 30% were aged 25-
29 years old, 17% were aged 30-34 years
old, and 14% were aged 35-40 years old.
3.2. SOCIO-DEMOGRAPHIC
CHARACTERISTICS
The socio-demographic characteristics
examined within the questionnaire included
nationality, ethnicity/cultural background,
sexual orientation, current accommodation
status, county and area of residence, level of
education, employment status, and
occupation. The results for each of these
variables are presented in the tables below.
As depicted in Table 8, the sample
comprised 8 different nationalities, with a
large majority of participants being Irish
nationals.
Table 9 illustrates the ethnic/cultural
background of the sample. While the majority of
participants were White Irish (80.9%), there was
a diverse mix of ethnicities among the sample.
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Total Sample
Participants (N) 89
Range (age) 18-40
Mean (age) 26.91
Median (age) 26
Std. Deviation (age) 5.87
TABLE 7 Descriptive Statistics for the Total Sample
n %
Irish 80 89.9
Brazilian 3 3.4
Spanish 1 1.1
Latvian 1 1.1
British 1 1.1
Dutch 1 1.1
Iranian 1 1.1
Polish 1 1.1
Total 89 100
TABLE 8 Nationality
n %
White Irish 72 80.9
Any other (including mixed background) 7 7.9
White Irish Traveller 3 3.4
Any other white background 3 3.4
Black or black Irish – African Origin 1 1.1
Black or Black Irish - any other Black background 1 1.1
Asian or Asian Irish – Chinese origin 1 1.1
Asian or Asian Irish - any other Asian background 1 1.1
Total 89 100
TABLE 9 Ethnic/Cultural Background
Table 10 displays the sexual orientation of
participants. Just over 90% of respondents
reported a heterosexual orientation, whereas
less than 10% reported a homosexual or
bisexual orientation.
As illustrated in Table 11, the most common
categories of accommodation status
reported were parental home and private
rented accommodation. Other
accommodation types included council
housing (n=3), partners residence (n=2),
and aunt/uncle s residence (n=2).
Table 12 highlights that the majority of
respondents resided in Dublin (89.3%).
Overall, less than 3% of respondents
resided in counties outside of Leinster.
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n %
Heterosexual 80 90.9
Homosexual 5 5.7
Bisexual 3 3.4
Total 88 100
TABLE 10 Sexual Orientation
*Missing Observations=1
*Missing Observations=5
n %
Parental home 37 41.6
Private rented accommodation 34 38.2
Own home 7 7.9
Emergency accommodation 3 3.4
Staying with friends (non-tenant) 1 1.1
Other accommodation 7 7.9
Total 89 100
TABLE 11 Current Accommodation Status
TABLE 12 County of Residence
n %
Dublin 75 89.3
Rest of Leinster 7 8.3
Outside of Leinster 2 2.4
Total 84 100
As illustrated in Table 13, participants, who
were residing in Dublin, reported a wide
range of areas of residence. Postcodes
which were noted most prevalently included
Dublin 7 (14.7%) and Dublin 8 (12%).
There was a varied level of education
completed among respondents. Table 14
illustrates that the most common level of
education completed was lower secondary
(34.1%), followed by higher secondary
(22.7%) and third level non-degree
(20.5%).
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n %
D1 4 5.3
D2 1 1.3
D3 4 5.3
D4 1 1.3
D5 6 8
D6 1 1.3
D6W 1 1.3
D7 11 14.7
D8 9 12
D9 5 6.7
D11 6 8
D12 7 9.3
D13 4 5.3
D14 2 2.7
D15 1 1.3
D16 1 1.3
D17 4 5.3
D22 3 4
D24 1 1.3
County Dublin 3 4
Total 75 100
TABLE 13 Area of Residence of Dublin based Participants
n %
Third level degree or higher 11 12.4
Third level non-degree 18 20.5
Higher Secondary 20 22.7
Lower Secondary 30 34.1
Primary education 7 8
No formal education 2 2.3
Total 88 100
TABLE 14 Highest Level of Education Completed
*Missing Observations=1
As shown in Table 15, approximately two-
fifths of participants reported currently being
in some category of employment. However,
almost half of participants reported currently
being unemployed.
Respondents reported a broad assortment
of occupations, which are displayed in 
Table 16.
Skilled trade was the most prevalently
reported class of occupation with just under
a third of respondents reporting vocations
such as carpenter, electrician, plumber or
mechanic. Occupations within the spectrum
of the health industry (e.g. gym
management, fitness instructor, nutritionist),
were reported by just over 10% of
respondents, as were occupations within the
retail/sales industry, and the security
industry. A large number of participants
neglected/declined to state an occupation.
3.3. USE OF PIEDs
Within the use of PIEDs section of the
questionnaire, participants were asked
questions around motivation for PIED use,
use of AAS, history of use, nature of use,
and use of ancillary compounds and post-
cycle substances. Results pertaining to
PIED use are presented below.
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n %
Unemployed 45 48.9
Employed full-time 19 20.7
Employed part-time 10 10.9
Student 10 10.9
Self-employed 5 5.4
Employed on employment scheme 2 2.2
Other employment status 1 1.1
TABLE 15 Employment Status
*3 participants reported being students and employed part time
n %
Skilled Trade 21 30.9
Health Industry 8 11.8
Retail/Sales 8 11.8
Security 7 10.3
Hospitality 6 8.8
Engineering/IT 4 5.9
Manual Labour 4 5.9
Logistics/Driver 3 4.4
Public Service 2 2.9
Student 2 2.9
Modeling 2 2.9
Social Care 1 1.5
Total 68 100
TABLE 16 Occupation
*Missing Observations=21
Table 17 highlights motivations for PIED
use. Among the most prevalently reported
motivations were to increase muscle mass
(91%), to increase strength (75.3%), to
look good (62.9%) and to increase
confidence (51.7%).
Table 18 outlines the descriptive statistics
relating to use of oral AAS and injected
AAS. Sixty-one participants reported use of
oral AAS, with the age of first use ranging
from 15-36 years old (M=22.71,
SD=4.64). Eighty-six participants reported
injecting use of AAS, with the age of first
use ranging from 16-39 years old
(M=23.84, SD=5.04).
Table 19 illustrates the sequence of AAS
use reported. Approximately 37% of
respondents started using oral steroids and
then progressed to injecting steroids, 18%
started using steroids orally and injecting
steroids at the same time, and 11% started
injecting steroids and then later used
steroids orally.
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n %
Increase muscle mass 81 91
Increase strength 67 75.3
To look good 56 62.9
Increase confidence 46 51.7
Dissatisfied with body shape 43 48.3
Recreational weightlifting 36 40.4
Bodybuilding 38 42.7
Decrease fat 33 37.1
Increase endurance 33 37.1
Occupational reasons 14 15.7
Rehabilitate injury 13 14.6
Sport 12 13.5
Prevent injury 9 10.1
TABLE 17 Motivation for PIED Use
Oral Injected
Participants (n) 61 86
Mean (age of first use) 22.77 23.84
Median (age of first use) 22 22
Std. Dev. (age of first use) 4.64 5.04
Range (age of first use) 15-36 16-39
TABLE 18 Descriptive Statistics for AAS Use
n %
Started oral steroids and then later injected steroids 33 37
Only ever injected steroids 27 30.3
Started oral and injected steroids at the same time 16 18
Started injecting and then later oral 10 11.2
Only ever used oral steroids 3 3.4
Total 89 100
TABLE 19 Sequence of AAS Use
Table 20 illustrates the types of AAS which
participants reported using during their
current cycle and during their previous
cycles. While respondents reported current
and past use of a wide variety of AAS,
Testosterone (single/multi esters) was by far
the most prevalently used AAS during
current cycle (84%) and previous cycles
(77.5%). Other AAS which were commonly
being used during current cycles included
Nandrolone decanoate (31.3%) and
Trenbolone acetate (19.3%). Although other
AAS such as Oxandrolone, Drostanolone,
Methandrostenolone, Boldenone, and
Oxymetholone appeared to have been
frequently used during previous cycles,
respondents reported little use of these
substances during their current cycles.
There was a wide spread in terms of the
number of cycles of PIED use respondents
had undertaken over their lifetime. As
displayed in Table 21, just under half of
respondents were on either their first cycle
or second cycle of PIED use. Almost a fifth
of respondents were currently on their sixth
or higher cycle (18%).
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Current Cycle (%) Previous Cycles (%)
Testosterone (single/multi esters) 84.3 77.5
Nandrolone Decanoate 31.3 53.5
Trenbolone Acetate 19.3 35.2
Stanozolol 10.8 22.5
Oxandrolone 7.2 33.8
Drostanolone 7.2 22.5
Methandrostenolone 6 49.3
Boldenone 4.8 19.7
Oxymetholone 3.6 22.5
Trenbolone hexahydrobencylcarbonate 2.4 8.5
Mesterolone 1.2 8.5
Methenolone 1.2 14.1
Chlorodehydromethyltestosterone 0 14.1
Nandrolone Undecanoate 0 7
Fluoxymesterone 0 2.8
Formebolone 0 1.4
TABLE 20 Types of AAS used During Current Cycle and Previous Cycles
n %
First cycle 18 21.4
Second cycle 20 23.8
Third cycle 12 14.3
Fourth Cycle 12 14.3
Fifth Cycle 7 8.3
Sixth or Higher Cycle 15 18
Total 84 100
TABLE 21 Number of Current Cycle
*Missing Observations=5
Table 22 shows that there was a wide
variance in the length of participants usual
cycles. While the most commonly reported
length of usual cycle was 6-8 weeks, some
participants cycled for less than 5 weeks
whereas, others cycled PIEDs for a period
lasting more than 17 weeks.
Table 23 details where participants sourced
their AAS and highlights that almost two-
fifths of participants sourced their AAS from
friends (38.6%). Other sources which
featured prominently included through direct
contact with a supplier (25%), through a
supplier in gym (20.5%), and through the
internet (17%).
Table 24 depicts use of ancillary compounds
and post cycle treatment drugs used during
current cycle and during previous cycles.
Just over half of participants reported that
they engaged in post cycle therapy (n=48;
53.9%), whereas just under half reported
that they did not (n=41; 46.1%). Again,
participants reported use of a wide variety of
substances. The substances being used
most prevalently during current cycles
included Creatine (23.9%) and Aromatase
Inhibitors/Anti-Oestrogens (10.1%).
Substances which were most commonly
used during previous cycles included
Creatine (37.5%), HCG (27.2%),
Clenbuterol (25.8%), Aromatase
Inhibitors/Anti-Oestrogens (24.7%), and
Clomiphene citrate (21.3%).
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n %
Less than 5 weeks 16 18
6-8 weeks 26 29.2
9-11 weeks 17 19.1
12-14 weeks 14 15.7
15-17 weeks 7 7.9
More than 17 weeks 9 10.1
Total 89 100
TABLE 22 Length of Usual Cycle
n %
Friends 34 38.6
Direct contact with supplier 22 25
Supplier in gym 18 20.5
Internet 15 17
Direct contact with laboratory 2 2.3
Family 2 2.3
Tanning Salon 1 1.1
Other Source 4 4.5
TABLE 23 Acquisition of PIEDs
*Missing Observations=1
Current Cycle (%) Previous Cycles (%)
Creatine 23.9 37.5
Aromatase Inhibitors/Anti-Oestrogens 10.1 24.7
Human Chorionic Gonadotrophin (HCG) 8 27.2
Human Growth Hormone (HGH) 6.7 7.9
Clomiphene citrate 5.6 21.3
Testosterone Boosters 4.5 9.1
Clenbuterol 3.4 25.8
Ephedrine 2.2 18
Thyroid Agents 2.2 11.2
Tanning Agents 1.1 7.9
Growth hormone releasing hexapeptide/hormone 1.1 3.4
Insulin 1.1 2.2
Diuretics 1.1 2.2
Growth Hormone Fragment 1.1 1.1
Insulin Growth Factor (IGF) 1.1 0
Pro-hormones (PH) 0 5.6
Anti-acne medication 0 3.4
Gammahydroxybutyrate (GHB /GBL) 0 1.1
TABLE 24 Use of Ancillary Compounds/Post Cycle Treatment Drugs
3.4. SIDE EFFECTS EXPERIENCED
IN ASSOCIATION WITH USE OF
PIEDs
Participants were asked to detail the side-
effects which they had experienced (either
during, post, or off cycle) in association with
their use of PIEDs. A broad range of side-
effects were noted with Table 25
highlighting the most prevalent side-effects
experienced currently and previously.
3.5. TRAINING AND EXERCISE
Within this section of the questionnaire,
participants were asked questions around
participation in training and exercise, which
included type of exercise, frequency of
exercise, and participation in organised
sport. Results relating to the training and
exercise are presented below.
Almost all participants reported that they
participated in a regular training and
exercise programme (n=87; 97.8%). The
number of days participants participated in
training and exercise is illustrated in Table
26, which shows that just under half of
participants reported that they exercised
more than 5 days a week (46.1%).
In terms of type of training and exercise,
91% of participants reported participation in
weight training (n=81) and approximately
80% of participants reported participation in
cardiovascular exercise (n=71). The number
of sessions respondents participated in
weight training and cardiovascular exercise
is presented in Table 27. The most
frequently cited number of weight training
sessions per week was 5-7 (n=46) and the
most common number of cardiovascular
exercise sessions per week was 2-4
(n=49).
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Currently (%) Previously (%)
Increased sex drive 42.7 46
Increased appetite 41.6 49.4
Testicular atrophy 26 29.2
Increased aggression 23.6 38.2
Growth of excessive body hair 23.6 36
Sudden mood changes 22.5 31.5
Water retention 20.2 45
Acne 16.9 36
Anxiety 13.5 19.1
Insomnia 10.1 23.6
Muscle/Joint pain 10.1 22.5
Decreased sex drive 9 33.7
Depression 9 18
TABLE 25 Most Prevalent Side-Effects Experienced in Association with use of PIEDs
n %
None 2 2.2
Once a week 1 1.1
2-3 days a week 10 11.2
4-5 days a week 35 39.3
More than 5 days a week 41 46.1
Total 89 100
TABLE 26 Number of Days Exercised per Week
Weight Training (%) Cardiovascular Exercise (%)
None 9 20.2
One session a week 1.1 14.6
2-4 sessions a week 36 55.1
5-7 sessions a week 51.7 9
8-10 sessions a week 2.2 1.1
Total 100 100
TABLE 27 Frequency of Participation in Weight Training and Cardiovascular Exercise
Approximately 46% of respondents (n=41)
reported participation in organised sport, with
some participants engaging in more than one
category of sport. All of the participants
engagement in sport was at an
amateur/recreational level, with the exception
of 1 participant, who competed professionally.
Table 28 illustrates the types of sport played
and indicates that the most prevalently
reported types included bodybuilding (15.7%),
boxing (10.1%), and soccer (10.1%).
3.6. USE OF OTHER SUBSTANCES
Within the questionnaire, participants were
asked whether they had ever used other
substances, if used, what was the route of
administration, and which substances they had
used in the past month. The results emanating
from participants responses are described
below.
Table 29 shows that participants reported use
of an assortment of other substances.
Substances such as Alcohol (95.5%),
Tobacco (71.6%), Cannabis (68.2%), Cocaine
(56.8%), and Benzodiazepines (35.8%)
showed particularly high levels of lifetime use.
Recent use (defined as use during the past
month) of the aforementioned substances was
also relatively prevalent. It is also noteworthy
that participants reported injecting use of
Heroin (11.4%), Cocaine (5.7%), and New
psychoactive substances (2.3%).
3.7. INJECTING PRACTICES
Within the questionnaire, participants were
asked questions around where they learnt to
inject, method of injecting, injecting site,
injecting related injuries, physical injecting
environment social injecting environment,
administration of injection, and injecting risk
behaviours. Results pertaining to these
injecting practices are presented below.
As detailed in Table 30, the majority of
respondents (55%) reported learning to inject
from other PIED users. Just over 30% of
participants learnt to inject through a harm
reduction service or medical professional.
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n %
No participation in organised sport 48 53.9
Bodybuilding 14 15.7
Boxing 9 10.1
Soccer 9 10.1
Mixed martial arts 7 7.9
Kickboxing 4 4.5
Rugby 4 4.5
Swimming 4 4.5
Other sport 4 4.5
TABLE 28 Type of Organised Sport
n %
Other PIED users 44 55
Internet 20 25
Harm reduction service 19 23.8
Drug supplier 13 16.3
Medical Professional 7 8.8
Self-taught 4 5
Family/Friends 2 2.5
TABLE 30 Learning to Inject
Lifetime Use (%) Ever Injected (%) Recent Use (%)
Alcohol 95.5 0 62.5
Tobacco 71.6 0 52.3
Cannabis 68.2 0 39.8
Cocaine 56.8 5.7 17
Benzodiazepines 35.2 0 22.7
Ecstasy 23.9 0 3.4
Anti-depressants 19.3 0 8
New psychoactive substances 17 2.3 1.1
Methadone 13.6 0 9.1
Crack 11.4 0 1.1
Heroin 12.5 11.4 3.4
Methamphetamine 9.1 0 1.1
TABLE 29 Other Substances Ever Used, Ever Injected, and Recently Used
*Missing Observations=9
Table 31 illustrates the method of injection
used currently and previously. While
intramuscular injection was the most popular
method of injection among respondents,
subcutaneous and intravenous injection was
also reported, with some respondents using
multiple methods. All participants who
reported intravenous injection also reported
current/previous injecting use of heroin.
Table 32 displays the injecting site used
currently and previously by respondents.
Injection in to the Buttocks was by far the
most prevalently used site both currently and
in the past, with Deltoids and Quadriceps
being the next most frequently used
injecting sites.
A number of respondents had experienced
injecting related injuries. As shown in Table
33, Muscle pain (47.5%) and Bruising
(37.5%) were the most commonly
experienced injuries.
Table 34 illustrates the physical
environment, in which, respondents reported
injecting. Four-fifths of respondents
reported that they always injected at home,
whereas 2% reported that they always
injected at the gym.
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Currently (%) Previously (%)
Intramuscular 93.6 94.4
Subcutaneous 14.1 19.7
Intravenous 1.3 11.3
TABLE 31 Method of Injection Used
*Missing Observations=11 *Missing Observations=18
Home (%) Gym (%) Other (%)
Always 80 2 2
Sometimes 16 14 8
Never 4 84 90
TABLE 34 Physical Injecting Environment
*Missing Observations=9
Currently (%) Previously (%)
Buttocks 91 90.1
Deltoids 25.6 36.6
Quadriceps 20.5 22.5
Triceps 3.8 8.5
Biceps 2.6 4.2
Chest 1.3 2.8
Calves 1.3 1.4
Lower Back 0 2.8
TABLE 32 Injecting Site
*Missing Observations=11 *Missing Observations=18
n %
Muscle pain 38 47.5
Bruising 30 37.5
Abscesses 14 17.5
Scarring 6 7.5
Infections 4 5
Nerve damage 2 2.5
TABLE 33 Injecting Related Injuries
*Missing Observations=9
Table 35 depicts the social environment, in
which, the respondents reported injecting.
Over half of the respondents always injected
alone, whereas a quarter always injected
with others. Approximately two-fifths of
respondents sometimes injected with
others.
Table 36 shows that 71% of respondents
always injected themselves and 16% were
always injected by another person.
Approximately 13% sometimes injected
themselves and sometimes were injected by
another person.
Table 37 illustrates respondents  level of
reuse of injecting equipment and indicates
that while the vast majority never reused
their injecting equipment, there were
respondents who sometimes reused, and
always reused.
As displayed in Table 38, there were few
reports of respondents lending their used
injecting equipment to other parties, with the
bulk of respondents stating that they never
lent used needles, syringes, or other
injecting equipment to others.
Table 39 illustrates rates of borrowing
injecting equipment and suggests very low
levels, with 98% of respondents reporting
that they never borrowed used needles,
syringes, or other injecting equipment from
other people.
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Inject Alone (%) Inject with Others (%)
Always 56 25
Sometimes 19 19
Never 25 56
TABLE 35 Social Injecting Environment
*Missing Observations=9
Yourself (%) Another Person (%)
Always 71 16
Sometimes 13 13
Never 16 71
TABLE 36 Administration of Injection
*Missing Observations=9
Needles/Syringe (%) Other Equipment (%)
Always 2 3
Sometimes 14 11
Never 84 86
TABLE 37 Reuse of Injecting Equipment
*Missing Observations=9
Needles/Syringe (%) Other Equipment (%)
Always 0 0
Sometimes 5 5
Never 95 95
TABLE 38 Lending of Injecting Equipment
*Missing Observations=10
Needles/Syringe (%) Other Equipment (%)
Always 0 0
Sometimes 2 2
Never 98 98
TABLE 39 Borrowing of Injecting Equipment
*Missing Observations=9
3.8. BLOOD-BORNE VIRUSES
Within the questionnaire, participants were
asked whether they had been tested for
HIV, Hepatitis C, and Hepatitis B, when
they were last tested, the results of testing,
and whether they were receiving treatment
in the case of positive cases. The results
emanating from participants responses are
described below.
Table 40 shows the data relating to testing
for HIV. Approximately 48% of respondents
had ever been tested for HIV. However, an
equivalent amount had never been tested.
In terms of length of time since last HIV
testing, Table 41 displays that while almost
half of respondents had never been tested;
just over 30% had been tested within the
past year.
Table 42 illustrates that of those
respondents who had ever been tested for
HIV, there were no reports of a positive
status.
Table 43 presents the data regarding
participants testing for Hepatitis C.
Approximately 48% of respondents had
been tested for Hepatitis C, whereas a
slightly higher proportion (49%) had never
been tested.
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n %
Tested 42 47.7
Never tested 42 47.7
Not known if tested 4 4.5
Total 88 100
TABLE 40 HIV Testing
*Missing Observations=1
n %
Tested 42 47.7
Never tested 43 48.9
Not known if tested 3 3.4
Total 88 100
TABLE 43 Hepatitis C Testing
*Missing Observations=1
n %
Never tested 42 47.7
Less than 6 months 12 13.6
6-12 months 17 19.3
1-2 years 8 9.1
More than 2 years 5 5.7
Unknown 4 4.5
Total 88 100
TABLE 41 Length of Time Since Last HIV Testing
*Missing Observations=1
n %
Never tested 42 48.3
Negative 39 44.8
Positive 0 0
Unknown 6 6.9
Total 87 100
TABLE 42 HIV Test Results
*Missing Observations=2
Table 44 depicts the length of time since
last Hepatitis C testing and illustrates that
while almost half of respondents had never
been tested, approximately a third had been
tested within the past year.
Table 45 presents the Hepatitis C test
results of participants. Overall, 4.6% of
respondents reported a positive status.
When framed in terms of participants who
had been tested and knew their result;
positive statuses represented approximately
10% of these respondents. All participants
who reported being positive for Hepatitis C
had a past history of injecting drug use (all
four had previously injected heroin, one had
also previously injected cocaine and new
psychoactive substances).
Table 46 shows the treatment status of
participants who had tested positive for
Hepatitis C and indicates that one
participant had completed treatment,
whereas other participants were either
awaiting treatment (n=1), awaiting further
tests (n=1), or had declined treatment
(n=1).
Table 47 shows the data relating to testing
for Hepatitis B. Approximately 48% of
respondents had ever been tested for
Hepatitis B. However, an equivalent amount
had never been tested.
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n %
Never tested 43 48.9
Less than 6 months 13 14.8
6-12 months 16 18.2
1-2 years 9 10.2
More than 2 years 4 4.5
Unknown 3 3.4
Total 88 100
TABLE 44 Length of Time Since Last Hepatitis C Testing
*Missing Observations=1
n %
Not tested 43 49.4
Negative 36 41.4
Positive 4 4.6
Unknown 4 4.6
Total 87 100
TABLE 45 Hepatitis C Test Results
*Missing Observations=2
n %
Tested 42 47.7
Not tested 42 47.7
Not known if tested 4 4.5
Total 88 100
TABLE 47 Hepatitis B Testing
*Missing Observations=1
n %
Completed treatment 1 25
Awaiting treatment 1 25
Awaiting further tests 1 25
Declined treatment 1 25
Total 4 100
TABLE 46 Treatment Status for Hepatitis C
Table 48 displays that while almost half of
respondents had never been tested for
Hepatitis B; over 30% had been tested
within the past year.
Table 49 illustrates that of those
respondents who had ever been tested for
Hepatitis B, there were no reports of a
positive status.
Table 50 illustrates that approximately 34%
of respondents had been vaccinated for
Hepatitis B, whereas 62% of respondents
had not been vaccinated.
3.9. HARM REDUCTION SERVICE
UTILISATION
Approximately three-fifths of respondents
had previously attended a harm reduction
service (n=52; 59.8%), whereas two-fifths
were attending for the first time (n=35;
40.2%). As illustrated in Table 51,
respondents primary motivations for
attending services included to obtain
injecting equipment (98.8%) and for safer
injecting advice (67.1%).
3.10. PERSPECTIVES ON HARM
REDUCTION SERVICES
A further aim of the present study was to
explore participants  perspectives around
their experience and interaction with harm
reduction services. Accordingly, qualitative
data were collected which consisted of
participant responses on three open-ended
questions; “what has your experience been
like so far interacting with harm reduction
and needle exchange services”; “have you
any suggestions for services you would like
to see offered to you in the future”; and “are
there any other comments you would like to
make”. A large majority of the sample
(n=85, 95%) provided responses to these
questions. Data were analysed using
inductive thematic analysis, which was
conducted in line with the framework
outlined by Braun and Clark (2006).
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n %
Never tested 42 47.7
Less than 6 months 13 14.8
6-12 months 16 18.2
1-2 years 9 10.1
More than 2 years 4 4.5
Unknown 4 4.5
Total 88 100
TABLE 48 Length of Time Since Last Hepatitis B Testing
*Missing Observations=1
n %
Yes 30 34.5
No 54 62.1
Unknown 3 3.4
Total 87 100
TABLE 50 Vaccinated for Hepatitis B
*Missing Observations=2
n %
Obtain injecting equipment 84 98.8
Safer injecting advice 57 67.1
Obtain condoms 7 8.2
Medical service 6 7.1
Total 87 100
TABLE 51 Motivation for Attending Harm Reduction Services
*Missing Observations=4
n %
Never tested 42 50
Positive 0 0
Negative 40 47.6
Unknown 2 2.4
Total 84 100
TABLE 49 Hepatitis B Test Results
In total four prominent themes emerged
during the course of analysis. Two of these
themes related to participants experiences
of harm reduction services and are
illustrated in Table 52. Participants
interactions with harm reduction and needle
exchange services were generally described
in terms of being a positive and useful
experience. Within this theme,
respondents expressed that their experience
had been “positive” and outlined that they
had found services useful for “information”,
“getting sterile injecting equipment”, as well
as learning about safer injecting practices.
One respondent also referenced that he
found the non-judgmental position of harm
reduction services helpful, stating that
“workers do not judge you”. While a majority
of respondents expressed positive
sentiments towards services, a number
detailed that there was also a negative
aspect to their experiences. In particular,
individuals who used PIEDs indicated that
the presence of users of other substances
within harm reduction services and needle
exchanges created an intimidating
atmosphere, which was described as
being “uncomfortable”, “nerve wracking” and
“off-putting”.
The additional two themes which emerged
were related to participants  perspectives on
future service provision and are presented in
Table 53. Respondents proposed a range of
improvements to existing service
provision. Within this theme, the most
prominently emphasised suggestions were
for “increased medical services” and “more
information on steroids”. Additional
propositions for service enhancement, which
were less prevalently articulated, included
the provision for more injecting equipment to
be supplied within the needle exchange,
“more needle variety”, “information available
in other languages” and a supervised
“injecting room”. Respondents also
described that there should be more
advertisement of the service in order to
enhance awareness among the general
community of PIED users. 
The final theme which emerged was
centered on respondents  desire for a PIED
specific service. As illustrated in Table 53,
service users remarked that they would like a
steroid specific service, which was
specialised to cater for their particular needs
and medical issues. For some, this was allied
with the desire for a facility, which operated a
separate service for users of PIEDs.
30 merchants Quay Ireland PIEDs Research
Theme Sample Quotes Frequency
Positive and useful experience “Very useful service – got learned a thing or two” 75
“found out new information and I found out the 
correctway to inject”
Intimidating atmosphere “uncomfortable in service with other substance 11
users”
“General environment is difficult and would
stop people coming”
TABLE 52 Overview of Themes Relating to Experiences of Harm Reduction Services
Theme Sample Quotes Frequency
Improvements to existing “Improved medical service and improved 38
service provision information” 
“Opening hours in the evening”
Desire for a PIED specific service “Having a specific steroid service” 17
“separate steroid users from other substance 
users”
TABLE 53 Overview of Themes Relating to Perspectives on Future Service Provision
RESPONDENTS ALSO DESCRIBED THAT THERE
SHOULD BE MORE ADVERTISEMENT OF THE SERVICE
IN ORDER TO ENHANCE AWARENESS AMONG THE
GENERAL COMMUNITY OF PIED USERS. 
T
he concluding chapter of this study
will recount and summarise the
principal aspects of the present
research, and provide an integrative
assessment of the findings. Accordingly, the
aims and research questions are presented,
and the main findings are outlined. Following
this overview, findings are interpreted in the
context of previous research and evaluated in
terms of their implications. The elements of
design and methodology are appraised from
a critical perspective and suggestions for
future research are proposed.
4.1. RESTATEMENT OF AIMS AND
RESEARCH QUESTIONS
The objective of the present study was to
examine the profile and perspectives of
individuals attending harm reduction services
who are users of PIEDs. Specifically, the
study aimed to address nine primary
questions:
n What is the socio-demographic profile? 
n What are the motivations for PIED use
and history of use? 
n What is the nature of PIED use and
trends in PIEDs use? 
n What are the side-effects experienced in
association with use of PIEDs? 
n What are the patterns of poly-substance
use? 
n What is the training and exercise profile? 
n What are the injecting practices? 
n What are the levels of testing for BBVs,
prevalence of BBVs, and uptake of
treatment for BBVs? 
n What are PIED users perspectives on
harm reduction services? 
4.2. OVERVIEW OF KEY FINDINGS 
Within this section, the key findings are
described in accordance with the research
questions posed within the current study.
What is the socio-demographic profile?
The average PIED user in the present study
was approximately 27 years of age, although
the age of participants ranged from 18 to 40
years old. All participants were male and
significantly, no female PIED users
presented during the period of data
collection. While the sample was comprised
of eight different nationalities, the vast
majority were Irish nationals (90%). The
dominant ethnic/cultural background was
White Irish (80.9%), with few participants
reporting Black or Asian backgrounds. Most
of the participants reported a heterosexual
sexual orientation (90.9%). The most
common categories of current
accommodation status reported were
parental home (41.6%) and private rented
accommodation (38.2%), with almost 85%
of participants residing in Dublin. There was
a varied level of education completed among
respondents with the most widespread levels
of education completed being lower
secondary (34.1%), higher secondary
(22.7%) and third level non-degree (20.5%).
Almost half of the participants (48.9%) were
currently unemployed and just under a fifth
(20.7%) were in full-time employment.
What are the motivations for PIED use
and the history of use?
Among the most prevalent motivations for
PIED use were to increase muscle mass
(91%), to increase strength (75.3%), to look
good (62.9%), and to increase confidence
(51.7%). Almost all participants (96.6%)
reported lifetime injecting use of AAS, with
the average age of initiation being
approximately 24 years old. The youngest
onset of injecting use was sixteen years old
and the oldest was thirty-nine years.
Approximately 69% of participants reported
lifetime use of oral AAS. The average age of
initiation was approximately 23 years old,
with the age of first use ranging from fifteen
to thirty-six years. In terms of the sequence
of AAS use; approximately 38% of
respondents started using oral steroids and
then progressed to injecting steroids, 18%
started using steroids orally and injecting
steroids at the same time, and 11.5%
started injecting steroids and then later used
steroids orally.
What is the nature of PIED use and
trends in use?
There was a wide spread in terms of the
number of cycles of PIED use respondents
had undertaken over their lifetime. Just
under half of respondents were on either
their first cycle or second cycle of PIED use.
Almost a fifth of respondents had completed
five or more cycles (18%). 
The most commonly reported length of usual
cycle was 6-8 weeks (29.2%). However in
just over 10% of cases, the length of usual
cycle was more than seventeen weeks. In
terms of the AAS being used; while
respondents reported current and past use of
a wide variety of AAS, Testosterone
(single/multi esters) was by far the most
prevalently used AAS during current cycle
(84%) and previous cycles (77.5%). 
Other AAS used previously/currently
included Nandrolone decanoate and
Trenbolone acetate. Although other AAS
such as Oxandrolone, Drostanolone,
Methandrostenolone, Boldenone, and
Oxymetholone appeared to have been
frequently used during previous cycles,
respondents reported little use of these
substances during their current cycles.
In terms of the use of ancillary compounds
and post cycle treatment drugs; the
substances being used most prevalently
during current cycles included Creatine
(23.9%) and Aromatase Inhibitors/Anti-
Oestrogens (10.1%). Substances which
were most commonly used during previous
cycles included Creatine (37.5%), HCG
(27.2%), Clenbuterol (25.8%), Aromatase
Inhibitors/Anti-Oestrogens (24.7%), and
Clomiphene citrate (21.3%).
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Chapter 4: Discussion
What are the side-effects experienced in
association with the use of PIEDs?
Participants described experiencng a broad
range of side-effects in association with their
use of PIEDs. Prominent side-effects which
had been previously experienced included
increased appetite (49.4%), increased sex
drive (46%), water rentention (44.1%),
increased aggression (38.2%), growth of
excessive body hair (36%), acne (36%),
sudden mood changes (31.5%), testicular
shrinkage (29.2%), decreased sex drive
(33.7%), insomnia (23.6%), muscle/joint
pain (22.5%), anxiety (19.1%), and
depression (18%). Although cited with less
frequency, participants reported currently
experiencing a range of side-effects similar
to those above.
What are the patterns of poly-substance
use?
Participants reported the use a wide variety
of substances within their lifetime, with
alcohol (95.5%), tobacco (71.6%), cannabis
(68.2%), cocaine (56.8%), and
benzodiazepines (35.8%) showing the
highest levels of lifetime use. It is also
noteworthy that a small number of
participants reported having ever injected
heroin (11.4%), cocaine (5.7%), and new
psychoactive substances (2.3%). Recent use
(within the past month) of other substances
was also frequently reported. Again, alcohol
(62.5%), tobacco (52.3%), cannabis
(39.8%), benzodiazepines (22.7%), and
cocaine (17%) were the substances with the
most prevalent recent use.
What is the training and exercise
profile?
Almost all participants reported that they
were engaged in a regular training and
exercise programme, with over 85% stating
that exercised four or more days a week. In
terms of type of training and exercise, 91%
of participants reported participation in
weight training and approximately 80% of
participants reported participation in
cardiovascular exercise. The most frequently
cited number of weight training sessions per
week was 5-7 and the most common
number of cardiovascular exercise sessions
per week was 2-4. Approximately 46% of
participants reported current participation in
organised sport, with some participants
engaging in more than one category of sport.
All of the participants engagement in sport
was at an amateur/recreational level, with
the exception of 1 participant, who competed
professionally. The most prevalently reported
categories of organised sport included
bodybuilding (15.7%), boxing (10.1%), and
soccer (10.1%).
What are the injecting practices?
The majority of respondents (55%) had
learned to inject from other PIED users,
while just over 30% of participants had
learned to inject through a harm reduction
service or medical professional. While
intramuscular injection was the most popular
method of injection among respondents,
subcutaneous and intravenous injection was
also reported, with some respondents using
a combination of methods. Injection in to the
buttocks was by far the most prevalently
used site, with deltoids and quadriceps being
the next most frequently used injecting sites.
Respondents had experienced a range of
injecting related injuries, with muscle pain
(47.5%) and bruising (37.5%) among the
most commonly experienced injuries. In
terms of the physical environment of
injection; four-fifths of respondents reported
that they always injected at home, whereas
2% reported that they always injected at the
gym. In terms of the social environment of
injection; over half of the respondents always
injected alone, whereas 25% always injected
with others. In terms of the administration of
injection; 71% of respondents were always
injected by another person and 16% always
injected themselves. The majority of
respondents stated that they had never
reused (84%), lent (95%), or borrowed
(98%) previously used needle or syringes.
What are the levels of testing for BBVs,
prevalence of BBVs, and uptake of
treatment for BBVs?
While approximately a third of participants
had last been tested for HIV in the past 12
months, just under half of respondents had
never been tested. Of those respondents
who had ever been tested for HIV, there
were no reports of a positive status. Similar
results emerged concerning testing for
Hepatitis C, which again illustrated that while
almost half of respondents had never been
tested, approximately a third had been tested
within the past year. However, there were
reports of positive cases, with 4.6% of
respondents indicating that they had tested
positive for Hepatitis C. When framed in
terms of participants who had been tested
and knew their result; positive statuses
represented approximately 10% of these
respondents. Significantly, all participants
who reported being positive for Hepatitis C
had a past history of injecting psychoactive
drug use. Results pertaining to the treatment
status of participants who had tested positive
for Hepatitis C indicated that they had either
completed treatment, were awaiting
treatment or further tests, or had declined
treatment. Just under half of participants had
ever been tested for Hepatitis B, with
approximately a third having last been tested
within 12 months. There were no reports of
a positive status for Hepatitis B and just over
a third of respondents had been vaccinated
against the virus.
What are PIED users’ perspectives on
harm reduction services?
Overall, participants described their
interaction with harm reduction services in
positive terms and articulated that services
were particularly useful for accessing sterile
injecting equipment and information relating
to PIED use. That being said, service users
also stated that the presence of users of
other psychoactive substances within harm
reduction services and needle exchanges
created an intimidating atmosphere, which
made them feel uncomfortable. In terms of
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service provision, the primary desire
expressed by respondents was for a
separate, specialised service which catered
for their medical needs and was dedicated
exclusively to PIED use. Other suggestions
for service provision included having more
information on steroids, information available
in other languages, more advertisement of
the service, longer opening hours, and a
supervised injecting room.
4.3. INTERPRETATION OF FINDINGS
Interpretation of the age and gender profile of
the sample indicates congruence with
previous research (see Table 1), in that, the
majority of participants were males in their
twenties. This accumulation of evidence may
suggest that this demographic range is
representative of the core group of adult
PIED users. While a proportion of the wider
socio-demographic characteristics of
participants were perhaps reflective of the
context in which the research was engaged
(i.e. individuals who are White Irish, residing
in close proximity to the target service), the
range in nationality, cultural background,
sexual orientation, level of education, and
occupation evident in the findings, supports
the notion that users of PIEDs attending
harm reduction services represent an
increasingly diverse group of individuals.
Given that stigma, discrimination, and other
barriers may impede groups such as females,
members of the travelling community, foreign
nationals, and sexual minorities in accessing
and connecting with drug and health services
(Gibbons, Manandhar, Gleeson, & Mullan,
2014; HSE, 2007; Lawless, 2003), the
issues of cultural competence, inclusiveness,
and accessibility would appear to be pertinent
subjects for those services engaging with
users of PIEDs.
The profile of individuals, who use PIEDs for
non-medical purposes, was once associated
with elite athletes but now encompasses a
more wide-ranging population of users
(Bahrke & Yesalis, 2004). The cohort of
PIED users sampled in the present study
appears to be consistent with the results
from international studies (e.g. Aitken et al.,
2002; Cohen, et al., 2007) which have
demonstrated that a high proportion of users
of PIEDs are recreational and non-elite
athletes, whose primary motivations for using
such substances revolve around increasing
muscle mass, enhancing physical strength
and improving physical appearance. Although
respondents reported being heavily engaged
in training, exercise, and organised sport,
participation in sport did not appear to be a
significant motivation associated with use of
PIEDs, whereas involvement in recreational
weightlifting and bodybuilding did seem to be
high motivators.
In terms of the trajectory PIED use, the
results concerning age of initiation also show
similarity to the previous evidence (e.g.
Cohen et al., 2007; Larance et al., 2008;
Peters et al., 1999), which has proposed
that the onset of PIED use typically occurs
around the mid-twenties. Almost all
participants had used injectable AAS, with
the popularity of injectable AAS over oral
compounds also being the dominant trend
within the wider literature. From a harm
reduction perspective this presents a
dilemma as although intramuscular injection
of AAS may reduce the likelihood of liver
damage (when compared to use of oral
AAS), injecting use presents the risk of
related injuries and BBV infections (Cohen et
al., 2007). As such, the use of oral or
injectable forms presents the risk of harm
and highlights the difficulty in attempting to
formulate harm reduction strategies relating
to the use of specific PIEDs, and
accentuates the challenges services face in
setting the boundaries of harm reduction
advice. With regard to the nature of PIED
use, the findings imply that varieties of
single/multi ester testosterone were the
most prevalently used AAS, which
complements the results from previous
research (Cohen et al., 2007). That being
said, the vast range of AAS and ancilliary
compounds being used by this group serves
to further convolute the development of harm
reduction programmes, and the training of
harm reduction professionals.
The broad range of side-effects experienced
by participants, which they attributed to their
use of PIEDs, show similarity to the physical,
behavioural, and psychological effects
described within the literature (see Table 3).
However, the findings of the present study
did not examine any causal links between
use of substances and side-effects, and
there remains a lack of definitive clinical
evidence surrounding the side-effects of
steroids. While this ambiguity may hinder the
development of interventions designed to
minimise the harm associated with side-
effects, the present study, as well as the
wider empirical evidence highlights that PIED
users perceive themselves as experiencing a
broad range of adverse effects.
Consequently, it would appear that in order
to effectively reduce the harm stemming
from the adverse side-effects of PIED use, a
multi-tiered approach may be required.
Poly-drug use, including the combination of
illicit drugs with alcohol, and sometimes,
medicines and non-controlled substances,
has become the dominant pattern of drug
use in Europe (EMCDDA, 2011). Evidence
from previous studies suggests PIED users
frequently use other illicit substances (see
Table 5) and the findings of the present
study signify that a relatively high proportion
of participants recently used illicit drugs,
particularly cannabis, benzodiazepines, and
cocaine. While examination of specific trends
of concomitant use of PIEDs and other illicit
substances were outside the scope of the
present study, the accumulation of findings
suggest that the harm reduction needs of
this group may extend to the use of other
substances.
The low rates of re-using, borrowing, or
lending used injecting equipment and
associated paraphernalia found in the
present study are consistent with findings
from international studies (e.g. Aitkens et al.,
2002; Cohen et al., 2007; Day et al., 2008;
Hope et al., 2013). Considering the
association between such injecting risk
behaviours and BBV infections, these
findings are a positive sign. A possible
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manifestation of the minimal level of injecting
risk behaviours is the low prevalence of BBV
infections found among the sample, which
again is consistent with the low rates found
in other studies (see Table 6). That being
said, a high proportion of the sample had not
been tested for BBVs previously meaning
that the prevalence reported herein may
represent a conservative estimate.
Furthermore, the small proportion of
individuals engaging in sharing of injecting
equipment, coupled with the numbers
injecting with other people and being injected
by another person, suggest that there is the
potential for hazardous injecting practices
and a corresponding risk of BBV
transmission. Additionally, the most prevalent
injecting sites being used by participants
(buttocks and deltoids) are hard to reach and
intramuscular injection in to these areas
requires a forceful injecting technique (Aitken
et al., 2002). As such, injection tends to be
imprecise and can lead to bleeding puncture
wounds, thus heightening the risk for BBV
infection. Such injecting practices may also
cause injecting related injuries, as was
evident in the experiences of individuals in
the present study.
Taken in combination, the results emphasise
the continued need for harm reduction
interventions, such as education around
injecting risk and safer practices, and
providing access to regular BBV screening,
in minimising the threat of personal and
public health concerns related to injecting
PIED use. As the establishment of harm
reduction approaches emerged in response
to the heightening incidence of BBVs and
the identification of injecting psychoactive
drug users as a high risk group (Butler,
1991), this development was primarily
reactive in nature, and it has proved difficult
to curtail the high prevalence of BBVs,
particularly HCV, within this population
(Ashton, 2003; & 2012). The current low
prevalence of BBVs among PIED users
represents the opportunity for a proactive
approach to be taken in order to maintain
this low prevalence, rather than reacting to
the prospective scenario when prevalence
has escalated (Aitken et al., 2002).
The findings in the present study concerning
the interaction between PIED users and
harm reduction services highlighted that a
high proportion of participants were attending
services for the first time, which may be
suggestive of further increases in the
prevalence of PIED using attendees. Given
that previous research has indicated that
PIED users are reticent to use services for
seeking information (e.g. Larance et al.,
2008), a further significant finding of the
present study was the relatively high
proportion of attendees who were motivated
to use services for the purposes of harm
reduction advice. The qualitative findings
describe that while interactions with harm
reduction services were experienced as
positive; there was a salient desire among
participants for a specialist service, which
was separate from other groups of IDUs.
Such findings are indicative of debate within
the wider literature as although there is
relative general consensus regarding the
potential for harm reduction approaches to
be employed with users of PIED, the most
appropriate and effective form of
interventions remains a point of contention
(e.g., see Kimergård & McVeigh, 2014).
4.4. APPRAISAL OF
METHODOLOGY
In order to draw conclusions regarding the
utility and reliability of the findings reported in
the present study, an assessment of the
research design and methodology is
required. In this section, the contribution of
these factors in arriving at findings is
considered, and an evaluation of the
methodological strengths and limitations is
presented.
The utilisation of a mixed method approach
was a considerable strength of the present
study as the use of quantitative and
qualitative approaches in concert facilitated
examination of the profile of PIED users
accessing harm reduction services, while
also exploring their perspectives around harm
reduction service provision. The use of
purposive sampling within the present study
meant that the research was focused on
PIED users who presented to harm
reductions services. While this was a
strategic decision made in the attempt to
compile an evidence base which could be
used to inform service provision, it meant
that the pool of potential participants to draw
from was relatively small, and moreover,
limits the generalisability of findings to the
wider population of PIED users.
The design of the research instrument was
augmented by critically appraising
instruments used in previous research and
adopting appropriate items. Confidence in
the research instrument is further bolstered
by the inclusion of multiple researchers, with
diverse areas of expertise, within the design
phase. That being said, the instrument relied
on self-report, and although this method is
generally considered to be a reliable and valid
form of gathering data relating to drug use
and associated variables (Bell, 1998), there
remains debate regarding the accuracy of
self-report. Furthermore, it has been
suggested that self-reported data regarding
socially undesirable, illegal behaviours, or
socially marginal attitudes, may generate
inaccuracy and bias (Harrison, 1995).
However, considering the data were
collected in the context of a low threshold,
non-judgmental harm reduction service, such
concerns may have been somewhat offset.
An area in the present study which may have
been impacted by self-report was the results
concerning BBVs. Given the lack of
biological testing, coupled with the relatively
small proportion of participants who had
been tested, the results herein should be
interpreted with caution.
A further limitation of the present study was
that quantitative analyses were descriptive in
nature and therefore, do not provide any
inferential information. Similar limitations are
evident with regard to the qualitative findings
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presented as they were drawn from open
ended questions rather than interview based
data, which led to a lack in depth of
perspective. Furthermore, individuals in the
current study who were attending services
for the first time may not have had the
opportunity to fully experience services. That
being said, the systematic approach to
analysing qualitative data, as well as the
inclusion of multiple researchers in the
process of analyses, does contribute to a
high level of confidence in these findings.
In summary, the research design, sampling,
and instrument employed herein represent
key strengths of the present study. However,
there were also a number of noteworthy
methodological concerns regarding the
generalisability of findings, reliance on self-
reported data, and lack of depth in terms of
statistical analyses and qualitative data. In
light of the dearth of previous research
concerning harm reduction and users of
PIEDs in an Irish context, the present study
intended to provide an exploratory overview
and serve as an initial building block from
which to base further investigation. As such,
it provides a useful examination of the
phenomenon of PIED use, the divergent user
characteristics and perspectives, and as
discussed within the next section, speaks to
a number of significant implications for future
practice and research.
4.5. RECOMMENDATIONS
The findings of the present study spotlight
the trend around the increasing prevalence of
users of PIEDs attending harm reduction
services. Within the following section,
consideration is given to the implications of
these findings in the form of a number of
recommendations.
4.5.1. Recommendations for practice.
n As a group, users of PIEDs represent a
minority at harm reduction services. The
increasing prevalence of attendees, who
are using such substances, means that
harm reduction service providers, and
indeed drug and health services in the
wider context, should expect to interact
with this group. 
n PIED users are a diverse group of
individuals. Service providers should
anticipate diversity among attendees who
are users of PIEDs and endeavour to
provide accessible, inclusive and
culturally competent services, which
recognise the issues facing individuals. 
n The trend of users of PIEDs attending
harm reduction services is a relatively
new phenomenon and represents a
major transition in the client base of such
services. Professionals engaging with
PIED users face several challenges in
catering for the needs of this group, and
therefore, the provision of specialist
training and education is particularly
necessary. 
n Given the range of personal and public
health concerns associated with the use
of PIEDs, the need for harm reduction
approaches to be integrated within a
continuum of care is readily apparent.
Interventions designed to minimise the
risk of harm should include the provision
of sterile injecting equipment, BBV
testing and vaccination, and health
services, as well as harm reduction
education and advice on BBV infections
and vaccinations, use of PIEDs,
associated side-effects, injecting
techniques, risk behaviours, diet and
training, use of other illicit substances,
and sexual health. 
n Existing harm reduction services are
traditionally geared towards users of
psychoactive substances. Given the
divergent profile and nature of substance
use among PIED users, there is a need
to develop a tailored approach in
response to the profile of harm within
this group. Expanding the range and
nature of models of practice may serve
to enhance accessibility, engagement,
and effectiveness. In particular, the
implementation and assessment of a
specialised PIED clinic on a trial basis
may be a beneficial development at this
time. 
n The use of PIEDs is associated with a
wide range of adverse impacts, which
may manifest in physical, psychological,
and/or behavioural domains. The varied
needs of this group require integrative,
multi-disciplinary approaches to be
considered, with emphasis on developing
inter-agency links and establishing care
pathways between general health
services, harm reduction services, and
mental health services. 
4.5.2. Recommendations for research.
n The evidence base surrounding the
worldwide prevalence of PIED use is
gradually expanding. There is however a
deficit of knowledge surrounding the
epidemiology of use in an Irish context.
As such, population based surveys,
which examine the national prevalence of
use among adults and adolescents,
would shed light on the patterns of use
and provide a basis for policy-making
and planning.
n The findings of the present study may
not be representative of the profile and
perspectives of users of PIEDs, who are
not attending harm reduction services.
Future research, which samples the
wider population of PIED users, would
provide a more comprehensive portrait. 
n Findings concerning BBVs in the present
study were based on self-report. In order
to ascertain a definitive prevalence,
future research which incorporates
serological testing is recommended. 
n In depth qualitative research would
provide a deeper understanding of the
experience and perspectives of PIED
users, and would further facilitate the
elicitation of their views regarding
appropriate service provision. 
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n Future research exploring the
perspectives of healthcare and harm
reduction professionals would identify
the challenges associated with engaging
with PIED users and assess the
feasibility of developing integrative,
multi-disciplinary approaches. 
n Research surrounding the effectiveness
of existing harm reduction service
provision within an Irish context is
required to evaluate the capacity of
services to minimise the harms
associated with the use of PIEDs. 
n Service provision in Ireland, and indeed
internationally, appears to be hindered
by the lack of public health policies and
practice guidelines relating to the use of
PIEDs. Research in this area is essential
in order to inform policy and equip
services with the infrastructure and tools
necessary to provide effective
interventions. 
4.6. CONCLUSION 
The present study aimed to examine the
profile and perspectives of individuals
attending harm reduction services who are
users of PIEDs. The findings highlight that
the profile of service users is made up of a
diverse range of individuals, with the
majority client group being males in their
twenties, who initiated use of steroids in
their late teens to mid-twenties. The group
were using a wide range of injectable and
oral steroids and ancillary substances, with
the primary motivation of enhancing physical
appearance. 
The sample reported experiencing a range of
side-effects, which they associated with their
use of PIEDs. Although relatively frequent
use of other illicit drugs was documented
among a proportion of the sample, the
prevalence of injecting risk behaviours and
BBVs appears to be low. In their
perspectives, experiences of harm reduction
services had been predominantly positive,
although there was a desire expressed for
services to be enhanced, particularly around
the provision of medical facilities. For many,
attending services was an intimidating
experience, which may have contributed to
the desire for a facility that provides a
separate service for users of PIEDs.
The present study has provided empirical
evidence concerning the emerging trend of
PIED users accessing services in an Irish
context, and emphasises that this group has
multiple harm reduction needs. Although the
significant levels of risk behaviours and
BBVs evidenced among other groups of
injecting drug users do not appear to have
been realised in this sample of PIED users,
it may not be representative of the wider
population of users, who are not attending
services. Considering the methodological
limitations of the present study and the
sparse evidence base surrounding the
interaction of harm reduction and PIED use
in an Irish context, this research provides an
initial overview and presents a number of
potential directions for addressing the needs
of this group. As such, it offers a useful
platform in future deliberations surrounding
the effective minimisation of harm
associated with the use of PIEDs.
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